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ABSTRACT 
 
Effect of Density Gradient Centrifugation on Quality and  
Recovery Rate of Equine Sperm. (May 2009) 
Ann Juliette Edmond, B.S., Texas A&M University  
Chair of Advisory Committee: Dr. Dickson D. Varner 
 
 
 
Density gradient centrifugation of sperm is a common assisted-reproduction 
procedure in humans used to improve semen quality.  The technique allows sperm 
separation based on their isopycnic points.  Sperm with morphologic abnormalities are 
often more buoyant, leading to their retention above centrifuged density gradients, with 
structurally normal sperm passing through the gradient.  Three experiments were 
conducted to evaluate the effects of tube size, sperm number following centrifugation, 
and density gradient volume (height) on stallion sperm quality and recovery rate in 
sperm pellets following centrifugation.  In all three experiments, equine semen was 
initially centrifuged to increase sperm concentration. In Experiment 1, one-mL aliquots 
were layered over EquiPure™ Bottom Layer (1-Layer) or over-tiered EquiPure™ Top 
and Bottom Layers (2-Layer). For Experiment 2, one-mL aliquots were layered over 
three different heights of EquiPure™ Bottom Layer in 15-mL or 50-mL conical-bottom 
tubes. For Experiment 3, four different aliquots containing a sperm load of 1-4x were 
layered over a constant volume of EquiPure™ Bottom Layer in 15-mL or 50-mL conical 
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bottom tubes. The tubes were then centrifuged.  Resulting sperm pellets were evaluated 
for morphologic quality, DNA integrity, motility and recovery rate.  
Sperm-EquiPure™ centrifugation yielded improvements in motility, morphology 
and DNA integrity parameters (P<0.05), as compared to controls. The 1-Layer method 
resulted in a higher recovery rate than the 2-Layer method (P<0.05).  Sperm processed in 
the 15-mL tubes yielded higher velocity and higher recovery rates than sperm processed 
in the 50-mL tubes (P<0.05). Within tube type, gradient volume did not impact 
parameters of semen quality or recovery rate.  An increase in sperm number for density 
gradient centrifugation resulted in a decreased recovery rate (P<0.05) when 15-mL tubes 
were used.  
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INTRODUCTION 
 Artificial insemination has become an integral part of the equine breeding 
industry.  This is based on widespread acceptance by horse breed registries for 
insemination with fresh semen, as well as cooled and frozen semen [1].  However, the 
number of sperm preparation techniques utilized in horse breeding programs is far less 
than with corresponding human procedures [2].  Many stallions are good candidates for 
alternative sperm preparation techniques because stallions, like men, are not chosen for 
mating based on fertility.  Stallions are selected as sires based on three key features: 
athletic performance record, pedigree, and conformation.  As such, subfertility is a 
relatively common occurrence among breeding stallions.  Some of these stallions 
produce semen which contains a high prevalence of sperm morphologic defects, reduced 
sperm motility, and reduced sperm chromatin quality.  Consequently, veterinarians and 
stud farm managers are often faced with semen quality problems similar to that seen in 
human assisted reproduction laboratories.  In both instances, semen-processing 
techniques can be applied in an attempt to improve sperm quality prior to insemination.   
Density gradient centrifugation is one of the most common sperm preparation 
techniques performed in human assisted-reproduction laboratories, and the procedure 
provides for enhancement of semen sperm quality [2].  Currently, Nidacon International 
AB (Mölndal, Sweden) produces commonly used discontinuous density-gradient media 
(PureSperm®). The product contains silane-coated silica particles that are incorporated  
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into a discontinuous gradient designed to permit separation of higher-quality from lower-
quality human sperm.   EquiPure™ is a discontinuous density-gradient manufactured by 
the same company.  The non-silica portion of the gradient media was modified from that 
used with human semen in an effort to optimize its use with stallion semen.  
Using the discontinuous-gradient centrifugation method applied with these 
products, semen is layered over two underlying states of media containing different 
concentrations of silica particles.  Centrifugation of this composite permits gravitational 
separation of sperm populations, based on their density, as well as separation of sperm 
from non-sperm particles such as epithelial cells, bacteria, viruses, and debris [2,3].  
Sperm with various morphologic abnormalities will be trapped with greater frequency in 
the upper layers of the gradient whereas; morphologically normal sperm tend to pass 
through the gradient.   
Within the last decade, extensive studies have been conducted world-wide using 
density gradient preparation combined with a sperm swim-up technique to remove 
viruses from ejaculates.  In human assisted-reproductive laboratories, HIV, hepatitis C 
virus or hepatitis B virus in semen samples were successfully removed with this 
application [4].  Similarly, use of EquiPure™ in conjunction with a sperm swim-up 
procedure eliminated a sexually transmitted virus, equine arteritis virus, from stallion 
semen [5].  
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OBJECTIVES 
 The objective of this thesis project was to evaluate the performance of a 
discontinuous density gradient (colloidal silica–particle solution) with equine sperm.  
Currently, the manufacturer protocol for the product EquiPure™ (Nidacon International 
AB, Mölndal, Sweden) consists of layering up to 1.5 ml semen over 2 ml of the Bottom 
Layer (80% density gradient) and 2 ml of the Top Layer (40% density gradient) in a 15-
ml centrifugation tube.  Experiment 1 compared the standard two-layer protocol with a 
one-layer (Bottom Layer only) protocol for density-gradient centrifugation of stallion 
sperm in 15-mL conical centrifugation tubes.  Experiment 2 evaluated the effects of 
gradient media height (28mm, 35mm, and 41mm) and centrifugation tube type (15-mL 
versus 50-mL conical centrifugation tubes) for density-gradient centrifugation.  
Experiment 3 studied the effects of semen volume/sperm number on quality and quantity 
of sperm recovered following density-gradient centrifugation.   The overall goal of the 
study was to develop methods to utilize and simplify density-gradient centrifugation 
techniques in an effort to maximize reproductive performance in subfertile stallions. 
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LITERATURE REVIEW 
Artificial Insemination 
 Artificial insemination plays a crucial role in the fertilization process for plants 
and flying insects in nature.  In the equine species, artificial insemination is a 
development by humans that has enhanced reproduction.  This process of placing 
stallion sperm into a mare’s uterus by using artificial means has many advantages over 
natural breeding in the horse industry.   These advantages include the ability to breed 
multiple mares with a single ejaculate, breeding a mare that has impediments that 
preclude natural mating (i.e., physical disabilities, failure to show behavioral estrus, or 
susceptibility to bacterial infection), increased safety for mare and stallion, and the 
ability to breed mares that are geographically remote from the stallion.  An improvement 
on the technique of artificial insemination is an ongoing process that is many years in the 
making.  
 Historically, it is thought that the practice of artificial insemination dates back to 
1322 and was first successful in a horse.  Allegedly, an Arab chieftain stole semen from 
a recently mated mare of a neighboring rival, diluted it in camel milk and deposited it 
into one of his own mares [6-8].  Artificial insemination in horses was not recognized 
again for many centuries.  In 1898, Walter Heape documented that a stallion with “faulty 
formation” was having difficulty “settling” mares. The owner was advised to artificially 
inseminate the mares.  As a result, 26 out of 29 mares became pregnant and were able to 
overcome a sterility problem [9].  For the next couple of years, artificial insemination 
was mainly used for the treatment of subfertility.  It was not until 1912 that Ivanov 
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compared artificial insemination to natural service in horses and yielded pregnancy rates 
of 79.5% and 43.2%, respectively [7].   
 Due to the military’s need for horses, artificial insemination research began 
expanding in European and Asian countries in the early to mid 1900s [10].  China and 
Russia utilized this technique in more than 600,000 mares and expanded their national 
herds between 1930 and 1960 [6,8].  During this time, several types of artificial vaginas 
were developed [10].  This allowed for the improvement of stallion management and 
semen collection, evaluation and insemination. 
 Once equine breed registries in the United States began accepting the use of 
artificial insemination, research concentrated on the development of semen extenders to 
protect and maintain longevity of sperm.  Semen extenders have the ability to protect 
sperm from cold shock, prevent growth of micro-organisms, and minimize detrimental 
effects of seminal plasma [11].  In 1957, Arhipov used a glucose-based diluent at a 1:6 
(semen: diluent) ratio to extend semen prior to insemination [12].  This was one of the 
first reports of diluting stallion semen.  Since then, milk-based semen diluents have 
become the most practical and effective in protecting equine sperm during storage.  
Batellier et al. conducted four breeding trials that tested the standard protocol with an 
experimental protocol by inseminating 173 mares with semen stored 24 h in INRA 82 or 
Kenney’s diluent (standard: skim milk diluent) at 4°C in anaerobic atmosphere yielded a 
pregnancy rate of 40%, and 178 mares artificially inseminated with semen stored 24 h in 
INRA 96 (new: chemically defined, milk-free diluent) at 15°C in an aerobic environment 
yielded a pregnancy rate of 57%(P<0.001) [13].  This experimental protocol showed 
  
 
6
potential for use in the field for stallions sensitive to cold shock, by improving fertility 
when compared to the standard protocol [13].   
  
Insemination Dose     
 Since the acceptance of artificial insemination by breed registries and its 
increasing popularity within the equine breeding industry, research focused on shipping 
semen both nationally and internationally.  One main concern was the size of the 
insemination dose required to maintain satisfactory pregnancy rates.  In 1969, Bowen 
states that the recommended dose varies from author to author: Berliner suggests that 
1x109 live sperm are adequate, while Cheng suggests 1x109 motile sperm, per dose [7].  
With the uncertainty and accepted death of spermatozoa during cooling when shipping, 
the insemination dose of 1x109 progressively motile spermatozoa is one recommended 
standard shipping dose used today [14].  However, for mares on stud-farms the standard 
insemination dose is between 250 and 500 million progressively motile sperm, and is 
dependent on the fertility of a given stallion [14].  Colorado workers concluded from 
their research that an insemination dose of 500x106 progressively motile sperm would 
achieve optimal pregnancy rates based on the management procedures of the time [15-
17].  A study conducted by Gahne et al. demonstrated that reducing the insemination 
dose to 300x106 progressively motile sperm did not yield a lower pregnancy rate [15]. 
An adequate insemination dose is the major limiting factor for the number of mares that 
can be successfully bred by an individual stallion. 
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 Uterine body insemination is known cause a transient postbreeding endometritis 
in virtually all mares, which usually resolves itself with 24 hours in normal mares [18].  
In cases of severe post-breeding endometritis cases (mainly older mares), mares often 
accumulate fluid [18].  By utilizing one of the techniques of gamete intrafallopian 
transfer, transrectally guided deep uterine insemination, or hysteroscopic insemination, 
sperm is deposited directly on the uterotubal papilla at the tip of the uterine horn 
ipsilateral to the ovary containing the dominant follicle [18, 19].  A goal set by 
inseminating a mare using one of these techniques would be to eliminate the post-
breeding endometritis. Other advantages that should be considered include 
cryopreserved semen that is of limited supply, semen from a subfertile stallion with 
limited sperm numbers, stallions that have an increased mare book to service, 
insemination of sex-sorted semen, and insemination with epididymal sperm [18].  Even 
though 500 x 106 progressively motile sperm has become an accepted insemination dose 
within the industry, research has demonstrated that most of the ejaculate is expelled 
rapidly from the uterus due to the relaxation of the cervix during estrus and that only 
0.0007% of inseminated sperm actually gain access into the oviducts [20].   
 Early studies involving low dose, deep uterine horn insemination were mainly 
with the hysteroscopic approach. In 1998, Vazquez et al. obtained 3 pregnancies out of 
10 when the mares were inseminated with 4 x 106 sperm in a 20µl volume dose [21].  At 
the same time, Manning et al. also had disappointing pregnancy results when they 
deposited 1 x 106 or 10 x 106 sperm hysteroscopically [22]. However, Morris et al. 
demonstrated that when inseminated only once with 14 x 106 motile, frozen-thawed 
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sperm, the pregnancy rates were similar when mares were inseminated by hysteroscopic 
(9/14) or conventional (8/12) technique. [23]. 
 In an attempt to have a more practical method and reduce time and expense 
required for hysteroscopic insemination, the use of a transrectally guided deep uterine 
technique was developed.  Similar to hysteroscopic insemination, results of pregnancy 
rates from different studies had a wide range.  Lindsey et al. deposited 5 x 106 sperm 
with this method and resulted in 0 out of 10 mares pregnant [24].  In another study, 43% 
(3/7) mares were impregnated when inseminated with 25 x 106 sperm [25].  When the 
transrectally guided method was compared to the hysteroscopic method in two studies, 
similar results in pregnancy rates were obtained.  Rigby et al. showed no statistical 
difference in pregnancy rates of the mares inseminated hysteroscopically (13/21;62%) or 
after transrectally guided deep uterine insemination (10/20; 50%) [26]. Brinsko et al. 
reported  that by depositing 3.3 – 3.6 x 106 progressively motile sperm 10 out of 18 
mares (56%) became pregnant by the transrectally guided method and 12 out of 18 
mares (67%) became pregnant when inseminated hysteroscopically [27].   
 When low dose, deep horn insemination techniques were used to try to help 
improve pregnancy rates of subfertile stallions the results have been unsatisfactory [28].  
Vazquez et al. concluded from their research that it was the suboptimal number of 
normal motile sperm that was used in the insemination dose [21].  However, by 
subjecting an ejaculate to a discontinuous density gradient centrifugation method prior to 
hysteroscopic insemination, the percentage of normal motile sperm is increased.  Morris 
et al. inseminated mares with 10 x 106, 5 x 106, or 1 x 106 Percoll® (Sigma-Aldrich) 
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treated motile sperm that resulted in conception rates of 60, 75 and 64%, respectively 
[29].  Another study with two subfertile stallions (per-cycle pregnancy rate of <20%) 
proved to the pregnancy rate with one stallion from 20 to 35% and resulted in 7 out of 8 
mares pregnant for the other stallion [28].         
 
Density Gradient Centrifugation 
 A stallion’s ejaculate is known to consist of different subpopulations of sperm.  
Sperm need to possess many attributes (motility, normal morphological features, normal 
DNA quality, etc.) in order for them to fertilize an oocyte.  Sperm may be infertile for a 
variety of reasons (i.e., one sperm may be infertile due to a lack of motility, while 
another due to acrosomal dysfunction) [30].  This is one reason suboptimal pregnancy 
rates exist in the horse breeding industry.  Ley et al. claim that a stallion should be 
expected to achieve at least a 90% seasonal pregnancy rate when bred artificially to 120 
mares in a single breeding season [31].  The success of the breeding of a stallion can be 
impacted when ejaculates consist of low numbers of normal, motile sperm which can 
contribute to a lower than expected fertility.  An approach to this problem is to increase 
the percentages of motile and morphologically normal sperm from semen.  
 Discontinuous density gradient centrifugation has been a standard procedure in 
human assisted-reproduction laboratories for the purification of sperm.  These gradient 
media separate sperm with differing buoyant densities into different layers.  The 
predominant product used in previous years was a colloidal polyvinylprrolidone (PVP)-
coated silica, termed Percoll® (Pharmacia Biotech AB, Uppsala, Sweden).  In 1983, 
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Oklahoma State University workers evaluated the efficacy of Percoll® on rabbit, human 
and bovine semen.  This study resulted that the progressively motile sperm recovered for 
all three species was higher when compared to the unfractionated semen [32].   
Prakash et al. found that, when compared to sperm separation method by swim-
up, differential gradient centrifugation with Percoll® resulted in selection of more 
human sperm with normal morphology [33].  Of the 74 samples, 34 showed 
improvement in the percentage of normal sperm after Percoll® centrifugation, while 
only 21 showed improvement when prepared by the swim-up method (P = 0.009) [33]. 
Chen et al.,  compared swim-up and Percoll® on the percentage of progressive motility, 
recovery of motile sperm, removal of debris, and percentage of morphologically normal 
sperm [34].  Although the swim-up samples had a higher percent of progressive motility, 
the Percoll® samples contained more motile sperm because the sperm concentration in 
the Percoll® samples was significantly higher (P<0.05) than the swim-up samples [34].  
The percent of morphologically normal spermatozoa increased for both procedures, 
when compared to the raw sample (P<0.05), but showed no significant difference when 
compared to each other [34].        
In 2000, Zini et al. concluded that even though both swim-up and Percoll® 
treatments improved mean sperm motility when compared to whole semen (73.0% ± 
3.0% and 65.6% ± 4.0% versus 52.0% ± 3.6%, respectively, P<0.005), swim-up reduced 
sperm with denatured DNA significantly while Percoll® did not when compared to 
whole semen (4.8% ± 1.2% and 13.6% ± 3.6% versus 10.1% ± 2.3%, respectively, 
P<0.001) [35].     
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When Pharmacia Biotech removed Percoll® from commercial use in assisted 
reproductive technology in humans in 1996 because of high endotoxin levels, several 
alternative products were introduced.  These included OptiPrep™(Greiner Bio-One, 
Axis Shield, Oslo, Norway), IxaPrep®(Medicult, Copenhagen, Denmark), Isolate® 
(Irvine Scientific, Santa Ana, CA), and PureSperm® (Nidacon International, 
Gothenburg, Sweden).  OptiPrep™ and Ixaprep® consist of an iodixanol solution, 
whereas Isolate® and PureSperm® are colloidal silane-coated silica particles.   
It was of great importance to find a substitute product for Percoll® which would 
give equal or better sperm separation results.  Centola and co-workers compared 
PureSperm® with Percoll® with respect to recovery rate, sperm motility, sperm path and 
progressive velocities, and sperm hyperactivation.  Their results showed no statistical 
difference for any of the motion parameters or motile count between the PureSperm® 
and Percoll® treatments [36].  In another study, Percoll®, PureSperm®, and swim-up 
method were evaluated to see how effectively each product separated out the sperm with 
chromatin/nuclear DNA anomalies [37].  Sperm from three fractions (wash, sediment, 
and swim-up) were evaluated [37].  No significant difference was observed with any 
fraction of the swim-up method or the 45% fraction of either PureSperm® or Percoll® 
[37].  However, in the 90% fraction both the PureSperm® and Percoll® possessed a 
significantly lower (P<0.001) percentage of sperm with nicked DNA and with poorly 
condensed chromatin [37].   
About the same time, McCann and Chantler made a comparison of Percoll® and 
IxaPrep® density gradients.  Unlike the previous experiments, IxaPrep® showed a 
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considerably lower recovery (P< 0.05) of spermatozoa in each of the samples as well as 
63.7% motility and 39.4% progressive motility when compared to 76.5% and 56.5% 
with Percoll® (P< 0.05) [38].  Morphological abnormalities was 68% ± 3.2 in neat 
semen, and reduced to 55% ± 5.5 after Percoll® separation and to 64% ± 7.0 after 
IxaPrep® separation [38].   
With the success in human assisted reproduction, density gradient centrifugation 
has increased both in research and clinical cases in other species.  In 1997, Turner and 
Arns presented a case at the Equine Nutrition and Physiology Society Annual 
Symposium that demonstrated that the percentage of progressive motile sperm following 
Percoll® treatment was higher than the other treatments measured.  Their data suggested 
that isolation on a Percoll® density gradient may enhance in vitro capacitation of stallion 
sperm [39].  Sieme et al. also tested Percoll® centrifugation on equine sperm, but had 
significantly lower motilities when compared to swim-up, glass wool, and glass wool 
sephadex filtration [40]. Percoll® was successfully used by Ock et al. to isolate round 
spermatids from bull testes [41]. The gradient recovered 86.7 ± 3.26% live cells 
compared with 70.8 ± 2.37% in the untreated cell preparation (P<0.01) [41].   
With the success of the product PureSperm® and the promising future of density 
gradient centrifugation in the equine industry, Nidacon International introduced a density 
gradient media (labeled as EquiPure™) specifically for separating and purifying equine 
sperm.  In 2002, Macpherson et al. examined the efficacy of EquiPure™ to separate 
higher quality of equine sperm by measuring morphologic and motility parameters [42].  
The results revealed a higher percentage of normal sperm (P=0.06) and higher total 
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motility and progressive motility (P<0.05) in the processed pellet than in the raw, 
unprocessed semen [42].  Subsequently, Morrell and Geraghty were successful in 
removing equine viral arteritis from stallion semen by utilizing a double processing 
technique (density gradient centrifugation [EquiPure™], washing, and swim-up) [5].  
Recently, Morrell et al. reported preliminary work which compared density gradient 
centrifugation (two layer media) to single layer centrifugation and indicated that for 
stallions with ejaculates within the normal range there was little difference between the 
two methods for motion characteristics [43].  Also, the recovery rate yielded from the 
single layer and the two-layer was 33.6 ± 9.8 and 31.5 ± 11.2, respectively [43].         
In the experiments above, density gradient centrifugation proved to separate 
higher quality equine sperm into the processed pellet [5,42-43].  Since these studies have 
shown that density gradient centrifugation of equine semen is useful for purifying sperm 
from an ejaculate, the next step in improving density gradient centrifugation and 
processing of semen might be to assess whether the standard two-layer gradient (40%-
80%) techniques could be simplified to one-layer gradient (80%).  In addition, it would 
be beneficial to determine if the size of centrifugation tube (15mL versus 50mL), depth 
of the density gradient, or sperm load on the gradient has an effect on sperm recovery 
rate and semen quality in the post-centrifugation sperm pellets. 
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MATERIALS AND METHODS 
 Three experiments were conducted to evaluate the effects of density-gradient 
density (one-layer versus two-layer), tube size (15-mL versus 50-mL conical tubes), 
gradient height (28mm [2mL], 35mm [3mL], or 41mm [4mL]), or sperm number (250 - 
2000 x 106) on sperm quality and recovery rate following density-gradient 
centrifugation.  Sperm motion characteristics, sperm morphologic features, and sperm 
DNA quality were evaluated in neat semen, and the same experimental endpoints and 
sperm recovery rate were determined in sperm pellets following density-gradient 
centrifugation semen. 
 
Stallions and Semen Collection 
 For each of the three experiments, three ejaculates from each of four stallions (n 
= 12) were used.   All stallions were sexually mature, light-horse breed, and sexually 
active.  Ejaculates were collected at 1- to  5-day intervals using an artificial vagina 
(Missouri-model; Nasco, Ft. Atkinson, WI, USA) equipped with an in-line nylon 
micromesh filter (Animal Reproduction Systems, Chino, CA, USA) to allow collection 
of gel-free semen.   Immediately prior to semen collection, the artificial vaginas were 
lubricated with approximately 3 mL of sterile non-spermicidal lubricant (Priority Care; 
First Priority, Inc., Elgin, IL, USA).  Each stallion was sexually stimulated by an 
ovariectomized mare and semen was collected using a phantom mare.  Once an erection 
was acquired, the stallion’s penis was rinsed with warm tap water and dried thoroughly.  
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Following semen collection, the gel-free semen sample was transported to an adjacent 
laboratory and placed in an incubator (37°C) prior to processing.  
 
General Semen Processing 
 The total sperm number in gel-free semen was estimated by measuring semen 
volume with a graduated cylinder and measuring initial sperm concentration using a 
fluorescence-based instrument (NucleoCounter SP-100; Chemometec A/S, Allerød, 
Denmark).  One-mL aliquots of well-mixed semen were immediately snap frozen on dry 
ice in 1-mL polypropylene tubes (Cryogenic vials [1.2-mL]; Corning Life Sciences, 
Lowell, MA, USA), then stored at -80oC until analyzed for the susceptibility of sperm 
chromatin to denaturation (i.e., Sperm Chromatin Structure Assay; SCSA). Also, one-
mL aliquots of well-mixed semen were immediately diluted in Buffered Formol Saline 
(BFS) in 1-mL polypropylene tubes (Cryogenic vials [1.2-mL]; Corning Life Sciences, 
Lowell, MA, USA), and stored at ambient temperature until analyzed for sperm 
morphology.  
 Aliquots of gel-free semen were immediately diluted with a pre-warmed (37oC) 
extender (INRA 96; IMV, Maple Grove, MN, USA) to a final sperm concentration of 
approximately 20 million sperm/mL for evaluation of initial sperm motility measures, 
using computer-assisted sperm motion analysis.  The INRA 96 extender was selected 
because it is free of particulate debris that could interfere with computerized sperm-
motility analysis.  
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Cushion Centrifugation Procedures 
 Semen was centrifuged by cushioned method to increase sperm concentration 
prior to semen application to density gradients [44].  Briefly, the extended semen (40 
mL) containing approximately 2-10 billion sperm was first loaded into polypropylene 
50-mL conical-bottom centrifugation tubes (Corning Life Sciences, Lowell, MA, USA), 
then 3.5 mL of cushion media (Cushion Fluid™; Minitüb, Tiefenbach, Germany; CF) 
was layered beneath the extended semen, using a blunt-tipped 3.5-inch spinal needle (18 
ga), attached to a sterile 5-mL syringe.  The tubes were then centrifuged (IEC Centra 
CL2; Thermo Scientific, Waltham, MA, USA) at 1000 x g for 20 minutes at ambient 
temperature. Following centrifugation, the supernatant was aspirated to a preset volume 
mark in the conical tubes (7.5-mL), and then the majority of the cushion medium was 
removed by aspiration.  The resulting sperm pellet was resuspended to a concentration of 
250 – 500 x 106 sperm/mL with INRA 96 extender, Sperm concentration of the 
resuspended semen was measured using a NucleoCounter SP-100 (NucleoCounter SP-
100; Chemometec A/S, Allerød, Denmark).  Aliquots of resuspended semen were 
appropriately secured for analysis of sperm morphology, motion parameters, and 
chromatin quality. 
 
Density Gradient Centrifugation Procedures 
 All density-gradient products were warmed to room temperature prior to use.  
Predetermined volumes (depending on the amount required for each experiment) of 
EquiPure™ Top Layer and Bottom Layers (Nidacon International AB, Mölndal, 
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Sweden) were transferred with a sterile 50-mL syringe from the manufacturer’s storage 
bottle into separate polypropylene 50-mL conical tubes for ease of pipetting.  
EquiPure™ Bottom Layer  was added to polypropylene 15-mL conical-bottom 
centrifugation tubes (Corning Life Sciences, Lowell, MA, USA) to volumes of two-mL 
(Experiments 1 and 2), three-mL (Experiment 2), or four-mL (Experiments 1, 2,and 3).  
The same product was added to polypropylene 50-mL conical tubes to volumes of nine-
mL (Experiment 2), 12.5-mL (Experiment 2), or 16.5-mL (Experiments 2 and 3).  
Volumes were measured using air-displacement pipettes (Rainin Instruments, Oakland, 
CA, USA).  For Experiment 1, two mL of EquiPure™ Top Layer  were carefully layered 
on top of two-mL  of EquiPure™ Bottom Layer for two-layer density-gradient 
preparation. 
 Previously centrifuged and resuspended semen was carefully layered onto the 
EquiPure™ density gradients (Fig 1; Corning Life Sciences, Lowell, MA, USA; 
CONICAL tubes).  One-mL aliquots were layered over each of the density gradients for 
Experiments 1 and 2.  One-, two-, three-, or four-mL aliquots were layered over density 
gradients for Experiment 3.  The loaded tubes were then centrifuged (Marathon 10K, 
Fisher Scientific, Pittsburgh, PA, USA) at 200 x g for 30 minutes at ambient 
temperature, using a swinging rotor.   Following density gradient centrifugation, all 
supernatant above the resulting sperm pellets was aspirated using a glass Pasteur pipette 
attached to a vacuum set at approximately 300-500 mm.Hg.   
 Sperm pellets were resuspended in individual 2-mL polypropylene tubes 
(Corning Life Sciences, Lowell, MA, USA) containing 500 µL of INRA 96 extender, 
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supplemented with 10% seminal plasma from a control stallion. Volumes of the post- 
centrifugation sperm pellets were carefully measured with an air-displacement pipette.  
A post-centrifugation sperm concentration was measured using a NucleoCounter SP-
100.  The sperm concentration and volume of the resuspended semen samples were 
measured, and then extended semen was prepared immediately for sperm motility 
analysis, was diluted in BFS solution for sperm morphology analysis, and was frozen in 
1-mL aliquots at -80 oC until analyzed for sperm chromatin integrity (SCSA).  
                     
 
 
 
 
 
Fig. 1 
Photograph of layering technique of semen over EquiPure™ gradient   
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Experimental Design 
Experiment 1 
To evaluate the effects of density gradient system on semen quality and sperm 
recovery rate, semen extended with INRA96 extender was subjected to cushioned 
centrifugation, as described above, and then sperm pellets were resuspended in INRA96 
extender to a concentration of 250 – 500 x 106 sperm/mL.  One-ml aliquots of this semen 
were layered over one of two density gradients ; 1) Two-mL EquiPure™ Top Layer over 
two-mL EquiPure™ Bottom Layer or 2) Four-mL EquiPure™ Bottom Layer.  All 
density-gradient centrifugations were performed using polypropylene 15-mL conical 
centrifugation tubes.  Following density gradient centrifugation, the contents of each 
centrifuge tube were aspirated to the level of the resulting sperm pellet.  The sperm 
pellet was transferred into INRA 96 extender as described above.   
Aliquots of resuspended semen samples were prepared immediately for CASMA, 
morphologic analysis or were frozen for later analysis of SCSA as described above.  The 
effect of discontinuous density gradient composition (one-layer versus two-layer) on 
sperm motion characteristics, sperm morphologic features, sperm chromatin integrity, 
and sperm recovery rate were examined. 
 
Experiment 2 
To examine the effects of centrifuge-tube type and density gradient volume on 
semen quality and sperm recovery rate, semen extended with INRA96 extender was 
subjected to cushioned centrifugation, as described above, and then sperm pellets were 
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resuspended in INRA96 extender to a concentration of  250 – 500 x 106 sperm/mL.  
One-ml aliquots of this semen were layered over density gradients of specified volumes 
in one of two centrifuge tube types, as follows: 15-mL centrifuge tubes containing two, 
three, or four mL of Bottom-Layer EquiPure™ gradient medium, or  50-mL containing 
nine, 12.5, or 16.5 mL of gradient medium (representing similar gradient heights of 
28mm, 35mm, and 41mm to the two-, three-, and four-mL gradients, respectively in the 
15-mL centrifuge tubes). Following density gradient centrifugation, the contents of each 
centrifuge tube were aspirated to the level of the resulting sperm pellet.  The sperm 
pellet was transferred into INRA 96 extender as described above.   
Aliquots of resuspended semen samples were prepared immediately for CASMA, 
morphologic analysis or were frozen for later analysis of SCSA as described above.  The 
effects of centrifugation-tube type and gradient volume on sperm motion characteristics, 
sperm morphologic features, sperm chromatin integrity, and sperm recovery rate were 
examined. 
 
Experiment 3 
 To examine the effects of sperm number applied to density gradient 
centrifugation on semen quality and sperm recovery rate, semen extended with INRA96 
extender was subjected to cushioned centrifugation, as described above, and then sperm 
pellets were resuspended in INRA96 extender to a concentration of 250 – 500 x 106 
sperm/mL.  One-mL to four-mL aliquots of this extended semen were layered over 
density gradients containing four mL of EquiPure Bottom Layer in 15-mL centrifugation 
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or 15 mL of EquiPure Bottom Layer in 50-mL centrifugation tubes (representing a 
similar gradient height to that used in 15-mL tubes). Following density gradient 
centrifugation, the contents of each centrifuge tube were aspirated to the level of the 
resulting sperm pellet.  The sperm pellet was transferred into INRA 96 extender as 
described above.   
Aliquots of resuspended semen samples were prepared immediately for CASMA, 
morphologic analysis or were frozen for later analysis of SCSA as described above.  The 
effects of sperm number applied to gradients and centrifugation tube type on sperm 
motion characteristics, sperm morphologic features, sperm chromatin integrity, and 
sperm recovery rate were examined. 
 
Computer Assisted Sperm Motion Analysis (CASMA) 
 Sperm were analyzed by CASMA in a manner similar to that previously 
described [45].  Warmed (37 oC) analysis chambers (fixed height of 20 μm) affixed to 
microscope slides (Leja Standard Count 2 Chamber slides; Leja Products, B.V., Nieuw-
Vennep, The Netherlands) were slowly loaded with a 6-μL volume of extended semen.  
The slides were then placed on a stage (37 oC) and inserted into a CASMA instrument 
(IVOS Version 12.2L, Hamilton Thorne Biosciences, Beverly, MA, USA) for 
evaluation.  A total of 10 microscopic fields and a minimum of 500 sperm were 
examined per sample.  Preset values for the IVOS system consisted of the following: 
frames acquired – 45; frame rate – 60 Hz; minimum contrast – 70; minimum cell size – 4 
pixels; minimum static contrast – 30; straightness (STR) threshold for progressive 
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motility – 50; average-path velocity (VAP) threshold for progressive motility - 30; VAP 
threshold for static cells - 15; cell intensity – 106; static head size – 0.60 to 2.00; static 
head intensity – 0.20 to 2.01; static elongation – 40 to 85; LED illumination intensity – 
2200.  Experimental endpoints included: 1) percentage of motile sperm (MOT); 
percentage of progressively motile sperm (PMOT); mean curvilinear velocity (VCL; 
μm/s); mean average-path velocity (VAP; μm/s); mean straight-line velocity (VSL; 
μm/s), straightness ([VSL/VAP] x 100; %; STR), and linearity ([VSL/VCL] x 100; %; 
LIN).  
 
Sperm Chromatin Structure Assay (SCSA) 
 This assay was performed as previously described [46-48].  Individual semen 
samples were thawed in a water bath set at 37oC.  Approximately five-μL aliquots of 
thawed semen were mixed with 195 μL of a buffered solution which was then combined 
with a low pH (~ 1.2) detergent solution (400 μL) for 30 sec.  A solution of the 
heterochromatic dye, acridine orange, was added (1.2 mL at 4.0 μg/mL) to the sample 
and it was processed immediately (30 sec) on a flow cytometer (FACScan; Becton 
Dickinson, Mountain View, CA, USA).  The sample was allowed to pass through the 
tubing for two min before evaluation of cells.  Semen volume was adjusted so the flow 
rate approximated 200 cells/sec.  A total of 5000 events were evaluated per sample.  The 
flow cytometer was adjusted so that the mean green fluorescence was set at 500 channels 
(FL-1 @ 500) and mean red fluorescence at 150 channels (FL-3 @ 150).  Data were 
acquired in a list-mode and Sperm Chromatin Structure Assay values were calculated 
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using WinList™ software (Verity Software House, Topsham, ME, USA).  
Quantification of DNA denaturation in each cell was determined by the term alpha-t (αt), 
which is defined as the ratio of red/(red + green fluorescence).  The alpha-t (αt) 
designation is used to describe the relationship between the amounts of green (double-
stranded DNA) and red (single-stranded DNA) fluorescence.  The results were recorded 
as both scattergrams and frequency histograms.  The endpoint, Cells Outside the Main 
Population (COMPαt), was determined by selecting those sperm cells to the right of the 
main population, and represents the number of sperm cells outside the main population, 
as a percentage of the total number of sperm cells evaluated. 
 
Sperm Morphology 
 The percentages of morphologically normal sperm and percentages of sperm 
with specific morphological defects were determined using differential-interference 
contrast microscopy (Olympus BX60, Olympus America, Inc., Melville, NY, USA; 
1250 x magnification).  For analysis, 2-μL aliquots of semen were applied to a 
microscope slide, the fitted with a 22x22-mm No. 1 ½ cover-glass.  A total of 100 sperm 
per sample were examined to obtain the percentages of sperm with the following 
morphologic features:  normal, abnormal heads, abnormally small heads, abnormally 
large heads, nuclear vacuoles (crater defects), misshaped heads, abnormal acrosomes, 
detached heads, proximal droplets, small proximal droplets, large proximal droplets 
distal droplets, small distal droplets, large distal droplets, abnormal (swollen or irregular) 
midpieces, bent midpieces, bent tails,  coiled tails, and premature germ cells.    
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Statistical Analysis 
For each experiment, a  general linear model [49] was used to evaluate effects of 
treatments on experimental endpoints for semen quality and recovery rate. Semen 
subjected to density gradient centrifugation was also compared with semen subjected to 
cushioned centrifugation only and to semen that was simply diluted in extender and not 
subjected to any form of centrifugation.  The control groups were assigned the names of 
Group UC for uncentrifuged semen and Group CC for cushion centrifuged semen.  For 
Experiment 1, the EquiPure™ treatment groups were assigned the names of Group 1L 
for the one-layer and Group 2L for the two-layer.  The EquiPure™ treated samples were 
assigned the names of  Group 15-28mm, 15-35mm, 15-41mm, 50-28mm, 50-35mm, and 
50-41mm for 2, 3, 4, 9, 12.5, and 16.5mL EquiPure™ Bottom Layer, respectively in 
Experiment 2.  For Experiment 3, the EquiPure™ treatment groups were assigned the 
names of Group 15-1x, 15-2x, 15-3x, 15-4x, 50-1x, 50-2x, 50-3x, and 50-4x for the 
sperm load of 1-4x (250-500 x 106 sperm/mL). Variables measured as percentages were 
normalized by transformation to angles corresponding to arc sine of the square root of 
percentage for variance analyses.  Tabular data are presented as non-transformed values, 
for ease of interpretation.  The Student-Newman-Keuls multiple range test was used to 
separate main-effect means when treatment F ratios were significant (P < 0.05).     
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RESULTS 
 
Experiment 1 
 
 The main effects of the density-gradient composition (One Layer [Group 1L] 
versus Two Layer [Group 2L]) on measures of sperm quality values are presented in 
Tables 1 and 2. These treatment groups were also compared to extended semen that was 
not subjected to centrifugation (Group UC) and to extended semen that was subjected 
only to cushioned centrifugation (Group CC).  Group 1L yielded higher mean values for 
MOT, PMOT, VAP, LIN and COMPαt than did Group 2L (P<0.05).  Mean VCL, VSL, 
and STR were similar between these two treatment groups (P>0.05).  All measures of 
sperm morphology were also similar between the two treatment groups (P>0.05).   
Mean values for eleven of 27 experimental endpoints (MOT, PMOT, STR, LIN, 
COMPαt, morphologically normal, abnormal midpieces, bent midpieces, bent tails, 
coiled tails, and premature germ cells) yielded improved quality in Group 1L and Group 
2L, as compared to control treatments (Group UC and Group CC; P<0.05).  Mean VCL 
and VAP were similar between the Group 1L and Group UC (P>0.05) and both were 
higher than Group CC (P<0.05).  Mean VSL was lower in Group CC than Group UC, 
Group 2L and Group 1L (P<0.05).  Group UC yielded slightly greater values for 
abnormal heads than did Groups CC, 2L, and 1L (P<0.05).  Mean values for craters, 
small heads, abnormal acrosomes, proximal droplets, small proximal droplets and small 
distal droplets for were similar across treatment groups (P>0.05).  Groups 1L and 2L 
were similar to Group CC for mean percentages of large heads, misshaped heads, 
detached heads, and small distal droplets (P>0.05).   The mean percentage of large 
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proximal droplets and large distal droplets was slightly higher for the Group CC, as 
compared to the Groups UC, 1L, and 2L (P<0.05).   
 
 
Table 1: Main effects of treatment on sperm motility and chromatin quality (COMPαt) 
variables for four stallions (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
MOT 64d (5.4) 70c (4.8) 86b (2.8) 93a (0.8) 
PMOT 37d (7.3) 42c (7.1) 68b (4.1) 78a (2.0) 
VCL 165a (11.9) 149c (9.0) 155bc (9.9) 160ab (10.3) 
VAP 84a (7.3) 72b (5.4) 77b (6.5) 83a (6.3) 
VSL 64a (6.2) 54b (4.4) 62a (4.8) 67a (4.9) 
STR 74b (2.2) 73c (1.6) 81a (1.2) 81a (0.8) 
LIN 39c (1.8) 36d (1.3) 41b (0.7) 43a (0.8) 
COMPαt 9a (1.7) 9a (1.8) 4b (0.7) 3c (0.4) 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear      
     velocity (μm/s); VAP = average-path velocity (μm/s); VSL = straight-line velocity (μm/s); STR =   
     straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of    
     sperm with αt value outside the main population (%). 
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization 
prior to statistical analysis.  Original means and SEM values are presented in table to ease interpretation 
but statistical tests were conducted on transformed data. Among treatment and within laboratory 
parameter, means with different letters (a,b,c and d) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=12). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 
minutes (n=12). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL tubes 
and 200 x g for 30 minutes (n=12). 
d  Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL tubes 
and 200 x g for 30 minutes (n=12). 
†  Control Samples. 
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Table 2:  Main effects of treatment on sperm morphology 
variables for four stallions (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
Morphologically Normal 33b (5.2) 34b (5.5) 69a (3.8) 70a (3.0) 
Abnormal Heads 9a (0.7) 7b (0.5) 6c (0.5) 6bc (0.6) 
Craters 1a (0.2) 1a (0.4) 1a (0.2) 1a (0.2) 
Small Heads 2a (0.3) 2a (0.3) 1a (0.2) 2a (0.3) 
Large Heads 2a (0.5) 1b (0.4) 1b (0.1) 1b (0.1) 
Misshaped Heads 4a (0.6) 3ab (0.3) 3b (0.2) 3b (0.2) 
Abnormal Acrosomes 1a (0.2) 1a (0.2) 0a (0) 0a (0) 
Detached Heads 6a (1.1) 4b(0.6) 3b (0.7) 3b (0.6) 
Proximal Droplets 5a (0.8) 4a (0.7) 5a (0.6) 5a (0.7) 
Small Proximal Droplets 3a (0.7) 2a (0.6) 4a (0.6) 3a (0.5) 
Large Proximal Droplets 1b (0.2) 2a (0.4) 1b (0.2) 1b (0.1) 
Distal Droplets 4b (0.7) 6a (1.3) 5ab (0.6) 5ab (0.6) 
Small Distal Droplets 2b (0.5) 2ab (0.8) 3a (0.5) 3a (0.5) 
Large Distal Droplets 2b (0.3) 4a (0.7) 2b (0.3) 2b (0.3) 
Abnormal Midpieces 12b (1.8) 16a (1.5) 8c (0.9) 9c (0.9) 
Bent Midpieces 15a (2.4) 13a (2.0) 3b (0.7) 2b (0.6) 
Bent Tails 4a (1.2) 5a (1.3) 1b (0.5) 0b (0.2) 
Coiled Tails 10a (0.1) 9a (1.3) 2b (0.5) 0b (0.2) 
Premature Germ Cells 2a (0.5) 1b (0.3) 0b (0) 0b (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization                                               
   prior to statistical analysis.   Original means and SEM values are presented in table to ease  
   interpretation but statistical tests were conducted on transformed data. Among treatment and                                                 
   within laboratory parameter, means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=12). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for   
        20 minutes (n=12). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=12).          
d   Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=12).  
†  Control Samples. 
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 Significant stallion by treatment interactions (P<0.05) were detected for 13 of 27  
variables (MOT, PMOT, VCL, VSL, STR, LIN, COMPαt, morphologically normal, 
abnormal heads, distal droplets, bent midpieces, coiled tails, and premature germ cells ) 
and are presented in Tables 3 through 10.  The variable MOT was higher (P<0.05) in 
Group 1L than Group 2L for only one of four stallions.    For 3 of 4 stallions, mean 
MOT, was higher in Group 1L and 2L than Group UC and Group CC.  Mean PMOT was 
higher in Group 1L than Group 2L for two of the four stallions (P<0.05).  For three of 
the four stallions, mean PMOT was higher in Group 1L and Group 2L than Group UC 
and Group CC (P<0.05).  Mean VCL was similar across all 4 treatment groups for 
ejaculates from each of the four stallion studies (P>0.05).    For three of the four 
stallions, no differences were detected between Group 1L and Group 2L for mean VSL 
(P>0.05).  Mean VSL was higher in Group 1L than Group 2L for the remaining stallion 
(P<0.05).  Mean STR was similar between Groups 1L and 2L for three of four stallions 
(P>0.05), and mean LIN was similar between these groups for all four stallions.  The 
variable COMPαt was higher in Group 1L than Group 2L for one stallion only (P<0.05).    
The variable COMPαt was higher in the EquiPure™ treatment groups than both controls 
for all stallions (P<0.05).   
No difference was detected between Group 1L and Group 2L for the mean 
percentage of morphologically normal sperm in semen from each stallion tested 
(P>0.05).  Both EquiPure™ treatment groups (Group 1L and Group 2L) yielded a higher 
percentage of morphologically normal sperm than did the control groups (Group UC and 
Group CC) for each of the four stallions examined (P<0.05).  The percentage of 
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abnormal heads was higher in Groups 1L and 2L than in Group UC for 3 of 4 stallions 
tested.  The variable distal droplets was similar across treatment groups for three of four 
stallions (P>0.05).  For all four stallions, both control groups contained a higher 
percentage of bent tails than did the than the EquiPure™ treatment groups (P<0.05).  For 
three of four stallions, mean values for coiled tails were higher in control groups than in 
EquiPure™ treatment groups (P<0.05).  The percentage of premature germ cells was 
higher in Group UC than all other groups for one stallion (P<0.05).  No difference was 
detected among treatment groups for the remaining stallions (P>0.05).    
 Sperm recovery rate (%) was higher (P<0.05) in Group 1L (46.9 ± 0.08) than 
Group 2L (33.9 ± 0.07).  A stallion by treatment interaction was detected for recovery 
rate (P<0.05).  No differences were detected between Group 1L (50.7 ± 0.007) and 
Group 2L (45.3 ± 0.03) for mean sperm recovery rate for one stallion (P>0.05).  For 
each of the remaining three stallions, Group 1L yielded a higher mean sperm recovery 
rate than Group 2L (P<0.05).    
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Table 3: Effect of treatment on sperm motility and chromatin quality (COMPαt) 
variables for Stallion A (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
MOT 92a (2.1) 93a (0.3) 95a (0.6) 96a (0.6) 
PMOT 76b (3.8) 79ab (1.5) 83ab (1.5) 86a (0.9) 
VCL 196a (14.2) 174a (5.3) 170a (1.8) 178a (1.0) 
VAP 108a (10.5) 87a (3.5) 88a (0.3) 93a (0.3) 
VSL 87a (8.4) 68a (3.1) 70a (0.3) 74a (1.0) 
STR 81a (0.3) 78a (0.6) 80a (0.3) 78a (0.9) 
LIN 45a (1.3) 40b (0.6) 42ab (0.3) 43ab (0.6) 
COMPαt 5a (0.3) 4b (0.2) 2c (0.1) 2c (0.2) 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); 
VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
 VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); 
LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with αt value outside the main  
population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization 
prior to statistical analysis.  Original means and SEM values are presented in table to ease interpretation                                 
but statistical tests were conducted on transformed data. Among treatment and within laboratory            
parameter, means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
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Table 4:  Effect of treatment on sperm morphology  
variables for Stallion A (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
Morphologically Normal 60b (2.0) 62b (3.0) 89a (1.3) 85a (0.3) 
Abnormal Heads 11a (1.5) 6b (0.9) 3b (0.7) 5b (0.6) 
Craters 0a (0.3) 0a (0) 0a (0) 0a (0.3) 
Small Heads 2a (0.9) 2a (1.2) 1a (0.3) 1a (0) 
Large Heads 4a (1.0) 2a (1.5) 1a (0) 1a (0.3) 
Misshaped Heads 5a (0.9) 3a (0.9) 2a (0.3) 3a (0.3) 
Abnormal Acrosomes 2a (0.3) 0a (0.3) 0a (0) 0a (0) 
Detached Heads 2a (0.9) 2a (0.6) 0a (0) 0a (0.3) 
Proximal Droplets 3a (0.3) 3a (0) 2a (0.3) 2a (0.6) 
Small Proximal Droplets 2a (0) 2a (0.3) 1a (0.3) 1a (0.3) 
Large Proximal Droplets 1a (0.3) 1a (0.3) 1a (0.3) 1a (0) 
Distal Droplets 4a (1.9) 5a (0.3) 2a (0.3) 2a (0.3) 
Small Distal Droplets 2a (1.2) 3a (1.2) 2a (0.3) 2a (0.3) 
Large Distal Droplets 3a (0.9) 3a (0.9) 1a (0.3) 1a (0) 
Abnormal Midpieces 7ab (0.6) 10a (0.9) 4b (1.0) 6ab (1.8) 
Bent Midpieces 6a (1.7) 5a (1.0) 1b (0.3) 0b (0.3) 
Bent Tails 2a (1.2) 2a (1.0) 0a (0) 0a (0) 
Coiled Tails 4a (2.0) 2a (1.2) 0a (0) 0a (0.3) 
Premature Germ Cells 0a (0) 0a (0.3) 0a (0) 0a (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization                                               
   prior to statistical analysis.   Original means and SEM values are presented in table to ease  
   interpretation but statistical tests were conducted on transformed data. Among treatment and                                                 
   within laboratory parameter, means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
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Table 5:  Effect of treatment on sperm motility and chromatin quality (COMPαt) 
variables for Stallion B (mean ± SEM). 
 
Treatment 
 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc 
 
Group 1Ld 
 
MOT 60c (4.4) 72b (1.7) 91a (1.3) 94a (0.7) 
PMOT 33b (5.8) 41b (2.6) 73a (2.0) 80a (1.5) 
VCL 183a (9.9) 173a (4.6) 191a (3.5) 197a (1.9) 
VAP 99a (4.4) 88b (2.0) 104a (1.5) 109a (0.3) 
VSL 80b (3.2) 68c (1.5) 82b (0.9) 89a (0.6) 
STR 76c (0.6) 74d (0.3) 78b (0) 81a (0.3) 
LIN 42b (0.9) 39c (0.9) 44ab (0.3) 46a (0.7) 
COMPαt 3a (0.2) 4a (0.5) 2b (0.003) 2b (0.1) 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); 
     VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
     VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); 
LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with αt value outside the main  
population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization 
prior to statistical analysis.  Original means and SEM values are presented in table to ease interpretation                                 
but statistical tests were conducted on transformed data. Among treatment and within laboratory            
parameter, means with different letters (a,b,c and d) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20   
   minutes (n=3). 
 c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL tubes 
and 200 x g for 30 minutes (n=3).          
d  Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL tubes and     
   200 x g for 30 minutes (n=3).  
† Control Samples. 
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Table 6: Effect of treatment on sperm morphology 
variables for Stallion B (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
Morphologically Normal 35b (1.3) 32b (3.8) 68a (0.3) 70a (0.3) 
Abnormal Heads 10a (0.7) 6b (0.6) 7b (0.3) 5b (0.6) 
Craters 0a (0.3) 0a (0.3) 1a (0.3) 1a (0.7) 
Small Heads 2a (0.7) 1a (0.3) 1a (0.3) 2a (0.3) 
Large Heads 2a (0.7) 1a (0.3) 1a (0.3) 1a (0) 
Misshaped Heads 5a (1.9) 4a (0.7) 3a (0) 2a (0.3) 
Abnormal Acrosomes 0a (0.3) 1a (0.3) 0a (0) 0a (0) 
Detached Heads 5a (1.5) 3a (1.2) 2a (0.6) 2a (0.3) 
Proximal Droplets 6a (2.4) 6a (2.5) 8a (0.3) 8a (0.3) 
Small Proximal Droplets 5a (2.1) 4a (2.2) 6a (0.7) 6a (0.3) 
Large Proximal Droplets 1a (0.3) 2a (0.3) 2a (0.3) 2a (0) 
Distal Droplets 2b (0.6) 2b (0.7) 5a (0.3) 6a (0.6) 
Small Distal Droplets 1c (0.3) 1c (0.6) 3b (0.3) 5a (0.3) 
Large Distal Droplets 1a (0.9) 1a (0.3) 1a (0.3) 1a (0.3) 
Abnormal Midpieces 9a (2.0) 15a (3.8) 8a (1.2) 8a (0) 
Bent Midpieces 15a (2.4) 16a (0.9) 2b (0.7) 2b (0.3) 
Bent Tails 3a (0.3) 4a (0.6) 0b (0.3) 0b (0) 
Coiled Tails 15a (2.1) 13a (1.2) 1b (0.3) 0b (0.3) 
Premature Germ Cells 1a (0) 0b (0.3) 0b (0) 0b (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization                                               
   prior to statistical analysis.   Original means and SEM values are presented in table to ease  
   interpretation but statistical tests were conducted on transformed data. Among treatment and                                                 
   within laboratory parameter, means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
 
 
 
 
 
  
 
34
Table 7: Effect of treatment on sperm motility and chromatin quality (COMPαt) 
variables for Stallion C (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
MOT 58c (0.9) 61c (2.9) 72b (4.4) 90a (1.7) 
PMOT 24c (0.6) 28c (4.4) 48b (4.3) 70a (4.2) 
VCL 102a (7.0) 101a (3.7) 104a (2.0) 106a (1.2) 
VAP 50a (4.5) 46a (1.7) 47a (0.3) 53a (1.2) 
VSL 41a (4.0) 36a (1.7) 41a (0.6) 45a (1.2) 
STR 79b (0.3) 76b (1.0) 87a (1.0) 85a (1.2) 
LIN 40a (0.9) 36b (0.6) 66a (4.7) 43a (1.0) 
COMPαt 10a (0.3) 10a (1.2) 5b (0.9) 2c (0.3) 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); 
VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
 VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); 
LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with αt value outside the main  
population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization 
prior to statistical analysis.  Original means and SEM values are presented in table to ease interpretation                                 
but statistical tests were conducted on transformed data. Among treatment and within laboratory            
parameter, means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
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Table 8:  Effect of treatment on sperm morphology  
variables for Stallion C (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
Morphologically Normal 22b (0.7) 26b (1.9) 66a (4.7) 68a (0.9) 
Abnormal Heads 10a (0.3) 8ab (0.6) 6b (1.2) 5b (0.3) 
Craters 1a (0.3) 1a (0.3) 1a (0.3) 1a (0.3) 
Small Heads 2a (0.3) 2a (0.6) 2a (0.3) 2a (0.3) 
Large Heads 2a (0.3) 1a (0.3) 1a (0.3) 1a (0.3) 
Misshaped Heads 4a (0.3) 3a (0.7) 2a (0.3) 2a (0.3) 
Abnormal Acrosomes 1a (0.6) 1a (0.6) 0a (0) 0a (0) 
Detached Heads 9a (1.2) 4a (1.2) 4a (1.7) 4a (0.7) 
Proximal Droplets 7a (1.2) 4a (1.5) 5a (0.3) 4a (0.3) 
Small Proximal Droplets 5a (1.5) 1a (0.9) 3a (0.3) 3a (0.6) 
Large Proximal Droplets 2a (0.6) 3a (1.0) 1a (0.3) 1a (0) 
Distal Droplets 6a (1.5) 11a (3.9) 6a (0.9) 7a (0.6) 
Small Distal Droplets 3a (1.3) 5a (2.4) 5a (1.2) 5a (0.3) 
Large Distal Droplets 3b (0.3) 6a (1.5) 2b (0.3) 2b (0.3) 
Abnormal Midpieces 21a (1.8) 21a (1.0) 11b (1.5) 11b (0.9) 
Bent Midpieces 11a (0.6) 10a (0.9) 2b (0.6) 1b (0.9) 
Bent Tails 3a (1.5) 4a (1.0) 1a (0.6) 0a (0.3) 
Coiled Tails 9a (0.7) 10a (1.0) 1b (0.3) 1b (0) 
Premature Germ Cells 1a (0.7) 0a (0.3) 0a (0) 0a (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization                                               
   prior to statistical analysis.   Original means and SEM values are presented in table to ease  
   interpretation but statistical tests were conducted on transformed data. Among treatment and                                                 
   within laboratory parameter, means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
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Table 9: Effect of treatment on sperm motility and chromatin quality (COMPαt) 
variables for Stallion D (mean ± SEM). 
 
Treatment 
EquiPure™ Treated 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
MOT 46b (5.8) 52b (4.4) 87a (2.4) 92a (0.9) 
PMOT 14c (3.2) 18c (2.3) 66b (2.5) 76a (1.9) 
VCL 178a (6.8) 150a (0.7) 153a (10.2) 161a (6.0) 
VAP 77a (3.3) 67a (6.4) 69a (5.5) 76a (3.0) 
VSL 49bc (1.9) 43c (2.6) 54ab (3.5) 60a (1.2) 
STR 62b (0.6) 64b (0.9) 78a (1.2) 79a (1.2) 
LIN 30b (0.7) 29b (0.1) 38a (1.0) 39a (0.9) 
COMPαt 17a (1.6) 17a (1.7) 6b (0.9) 5b (0.4) 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); 
VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
 VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); 
LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with αt value outside the main  
population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization 
prior to statistical analysis.  Original means and SEM values are presented in table to ease interpretation                                 
but statistical tests were conducted on transformed data. Among treatment and within laboratory            
parameter, means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
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Table 10: Effect of treatment on sperm morphology  
variables for Stallion D (mean ± SEM). 
 
Treatment 
 
EquiPure™ Treated 
 
 
Laboratory 
Parameter* 
 
Group UCa† Group CCb† 
Group 2Lc Group 1Ld 
Morphologically Normal 16b (3.5) 13b (1.8) 56a (3.2) 58a (3.0) 
Abnormal Heads 5a (0.9) 8a (1.5) 7a (0.7) 9a (0.7) 
Craters 1a (0.6) 2a (1.2) 1a (0) 1a (0) 
Small Heads 0b (0.3) 2ab (0.3) 2ab (0.3) 3a (0.9) 
Large Heads 2a (1.0) 1a (0.6) 1a (0.3) 1a (0.3) 
Misshaped Heads 3a (0.9) 4a (0.7) 3a (0) 3a (0.3) 
Abnormal Acrosomes 1a (0.6) 0a (0) 0a (0) 0a (0) 
Detached Heads 9a (2.2) 6a (1.0) 5a (0.3) 6a (0.3) 
Proximal Droplets 2b (0.6) 2ab (0.3) 5a (0.6) 4ab (1.0) 
Small Proximal Droplets 1b (0) 1b (0.3) 3a (0) 3a (0.7) 
Large Proximal Droplets 1a (0.6) 3a (0.7) 2a (0.6) 1a (0.3) 
Distal Droplets 4a (0.3) 6a (1.0) 6a (1.5) 5a (0.6) 
Small Distal Droplets 1a (0.3) 1a (1.0) 3a (1.0) 2a (0.6) 
Large Distal Droplets 3b (0) 5a (0) 3b (0.3) 3b (0) 
Abnormal Midpieces 12a (2.8) 18a (2.3) 10a (0.6) 12a (2.0) 
Bent Midpieces 26a (2.0) 21a (2.6) 7b (0.3) 5b (0.9) 
Bent Tails 9ab (3.6) 12a (2.8) 3ab (0.9) 1b (0.7) 
Coiled Tails 12a (2.0) 12a (1.2) 4b (0.9) 1b (0.6) 
Premature Germ Cells 4a (1.2) 2a (0.6) 0a (0) 0a (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization                                               
   prior to statistical analysis.   Original means and SEM values are presented in table to ease  
   interpretation but statistical tests were conducted on transformed data. Among treatment and                                                 
   within laboratory parameter, means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for  
    20 minutes (n=3). 
c  Group 2L (Two Layer) =  EquiPure™ gradient with Top/Bottom Layers (2 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).          
d    Group 1L (One Layer) = EquiPure™ gradient with Bottom Layer only (4 mL each) in 15-mL  
    tubes and 200 x g for 30 minutes (n=3).  
†  Control Samples. 
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Experiment 2 
 
 Main effects for mean MOT, PMOT, VSL, COMPαt, morphologically normal 
sperm, and sperm with abnormal heads, craters, small heads, large heads, misshaped 
heads, abnormal acrosomes, detached heads, proximal droplets, small proximal droplets, 
large proximal droplets, distal droplets, small distal droplets, large distal droplets, bent 
midpieces, bent tails, coiled tails, or premature germ cells were not impacted by 
EquiPure™ treatment groups, which addressed centrifuge tube size and density gradient 
height (P>0.05; Tables 11 and 12). Mean curvilinear velocity was higher for sperm 
recovered in Groups 15-28mm (2mL), 15-35mm (3mL), and 15-41mm (4mL) than in 
Groups  50-35mm (12.5mL) and 50-41mm (16.5mL) (P<0.05).  Mean VAP was higher 
for Group 15-28mm (2mL) when compared to Group 50-41mm (16.5mL) (P<0.05);  
however, sperm subjected to EquiPure™ treatment in 50-mL tubes yielded slightly 
higher values for STR and LIN than sperm subjected to treatment in 15-mL tubes 
(P<0.05).  The percentage of abnormal midpieces was significantly lower is Group 15-
28mm (2mL) treatment than in Groups 15-35mm (3mL), 50-35mm (12.5mL), and 50-
41mm (16.5mL) treatment groups (P<0.05).   
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 When compared to the control groups (Groups UC and CC), the EquiPure™ 
treatment groups yielded improved values for mean MOT, PMOT, STR, COMPαt, 
morphologically normal, large proximal droplets, bent midpieces, and coiled tails 
(P<0.05).  Mean VCL was higher for sperm in the 15-mL conical tubes than both 
controls, and was higher for sperm in the 50-mL conical tubes than in Group CC 
(P<0.05).  All EquiPure™ treatment groups were yielded higher values than Group CC 
for mean VAP, VSL, and LIN (P<0.05).  Overall, nine of the nineteen morphological 
endpoints (craters, small heads, large heads, proximal droplets, distal droplets, small 
distal droplets, large distal droplets, bent tails, and premature germ cells) yielded similar 
values for all EquiPure™ treatment groups to that of both control groups (P>0.05).  
Group 15-28mm (2mL) was lower than control groups for mean abnormal heads 
(P<0.05),  For the experimental endpoint, mean misshaped heads, Group 50-35mm 
(12.5mL) yielded  lower values than did Group UC (P<0.05).  Mean percentages of 
abnormal acrosomes and small proximal droplets were higher in the Group UC than all 
EquiPure™ treatment groups (P<0.05).  Treatment Groups 15-41 (4mL), 50-35mm 
(12.5mL), and 50-41mm (16.5mL) were lower than Group UC for mean detached heads 
(P<0.05).  The mean percentage of abnormal midpieces was higher in Group CC than in 
Groups 15-28mm (2mL) and 50-28mm (9mL) (P<0.05).       
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Table 11: Main effects of treatment on sperm motility and chromatin quality (COMPαt) variables for four stallions  
(mean ± SEM). 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path  
     velocity (μm/s); VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %);  
     COMPαt  =      percentage of sperm with αt  value outside the main population (%).                                                                                             
§   Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a,b,c,d and e) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=12). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=12). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
 
 
 
 
                                  EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
MOT 71b (3.4) 73b (3.5) 90a (1.8) 91a (1.9) 91a (1.8) 89a (1.9) 89a (1.8) 88a (1.8) 
PMOT 42b (4.2) 46b (4.1) 73a (2.3) 73a (2.5) 74a (2.4) 72a (3.0) 72a (2.4) 70a (2.8) 
VCL 202c (7.0) 188d (10.2) 228a (6.0) 224ab (4.9) 223ab (5.5) 211bc (5.1) 207c (4.9) 202c (4.9) 
VAP 112ab (3.4) 96c (6.2) 122a (3.6) 121ab (3.1) 121ab (3.4) 116ab (2.9) 113ab (3.1) 111b (2.7) 
VSL 87a (2.8) 72b (4.6) 96a (3.1) 94a (2.8) 96a (2.9) 93a (2.5) 92a (2.6) 91a (2.3) 
STR 74d (0.6) 72e (0.6) 77c (0.8) 77c (1.0) 78c (0.9) 79ab (0.9) 79b (0.8) 80a (0.9) 
LIN 43c (1.2) 38d (0.8) 43c (0.8) 43c (0.7) 44bc (0.9) 45ab (0.9) 45ab (0.9) 47a (1.0) 
COMPαt 19a (3.1) 20a (3.1) 7b (1.8) 8b (1.7) 8b (1.9) 7b (1.4) 7b (1.7) 7b (1.3) 
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Table 12: Main effects of treatment on sperm morphology variables for four stallions (mean ± SEM). 
                                                         EquiPure™ Treatment 
Laboratory Parameters* 
 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
Morphologically Normal 38b (4.9) 38b (4.3) 63a (3.8) 61a (3.3) 61a (3.9) 62a (3.6) 61a (4.1) 59a (4.2) 
Abnormal Heads 7a (0.6) 5b (0.7) 3c (0.6) 3bc (0.6) 4bc (0.5) 4bc (0.6) 4bc (0.5) 4bc (0.8) 
Craters 2a (0.4) 2a (0.5) 1a (0.3) 1a (0.2) 1a (0.3) 1a (0.4) 2a (0.4) 2a (0.4) 
Small Heads 2a (0.4) 2a (0.4) 1a (0.4) 1a (0.3) 2a (0.3) 2a (0.3) 1a (0.4) 1a (0.3) 
Large Heads 1a (0.3) 0a (0) 0a (0.1) 1a (0.2) 0a (0.2) 0a (0) 0a (0) 0a (0) 
Misshaped Heads 2a (0.4) 1ab (0.4) 1ab (0.2) 1ab (0.6) 2ab (0.3) 1ab (0.3) 0b (0.3) 1ab (0.4) 
Abnormal Acrosomes 1a (0.3) 0b (0.1) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0.2) 0b (0) 
Detached Heads 12a (3.1) 8ab (1.2) 7ab (2.0) 7ab (1.8) 6b (1.2) 6ab (1.3) 5b (0.7) 5b (0.6) 
Proximal Droplets 14a (1.6) 17a (2.0) 14a (2.3) 14a (1.9) 15a (2.2) 14a (1.8) 14a (1.7) 15a (1.9) 
Small Proximal Droplets 9b (1.5) 11a (2.1) 12a (1.8) 12a (1.5) 12a (1.9) 13a (1.8) 12a (1.7) 13a (1.7) 
Large Proximal Droplets 5a (0.7) 5a (1.0) 2b (0.8) 2b (0.8) 2b (0.8) 1b (0.5) 2b (0.6) 2b (0.9) 
Distal Droplets 3a (0.6) 4a (1.2) 3a (0.7) 3a (0.7) 3a (0.8) 3a (0.6) 3a (0.8) 3a (0.7) 
Small Distal Droplets 1a (0.4) 3a (1.1) 3a (0.8) 3a (0.7) 3a (0.8) 3a (0.6) 2a (0.7) 3a (0.5) 
Large Distal Droplets 2a (0.3) 1b (0.3) 0b (0) 0b (0.1) 0b (0.1) 0b (0.2) 0b (0.3) 4b (0.3) 
Abnormal Midpieces 8bc (1.1) 11a (1.1) 5c (1.1) 8ab (0.8) 8abc (1.0) 6bc (0.8) 9ab (1.0) 9ab (1.0) 
Bent Midpieces 11a (4.1) 11a (3.5) 3b (1.1) 3b (1.1) 3b (1.0) 5b (1.7) 4b (1.5) 4b (1.5) 
Bent Tails 1a (0.2) 1a (0.4) 1a (0.3) 0a (0) 0a (0.3) 0a (0.3) 0a (0.3) 1a (0.4) 
Coiled Tails 4a (1.0) 5a (1.7) 2b (0.6) 1b (0.3) 2b (0.5) 1b (0.3) 1b (0.4) 1b (0.5) 
Premature Germ Cells 2a (0.6) 1a (0.4) 0a (0) 0a (0.1) 0a (0) 0a (0) 0a (0.2) 0a (0) 
§   Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=12). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=12). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
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 A significant stallion-by-treatment interaction (P<0.05) was detected for eleven 
of 27 variables (MOT, PMOT, STR, LIN, large heads, proximal droplets, small proximal 
droplets, large proximal droplets, large distal droplets, bent midpieces, and bent tails) 
and are presented in Tables 13 through 20.  No differences were detected for mean MOT 
and PMOT among EquiPure™ treatment groups for each of the four stallions (P>0.05).  
Mean MOT was higher in all EquiPure™ treatments than control groups for two of four 
stallions (P<0.05).  The EquiPure™ treatment groups for one stallion yielded similar 
values to Group UC (P>0.05) and higher values than Group CC (P<0.05) for MOT.  
Mean MOT was higher in Groups 15-28mm (2mL) and 15-41mm (4mL) than Group UC 
in one stallion (P<0.05) Mean PMOT was higher in all EquiPure™ treatment groups 
than both controls for three of four stallions (P<0.05).   EquiPure™ treatment groups for 
one stallion had higher values than Group UC for mean PMOT (P<0.05).   Within 
EquiPure™ treatment groups, no difference was detected for mean STR (P>0.05) for 
two of four stallions examined and values were higher in EquiPure™ treatment groups 
than control groups for two of four stallions (P<0.05)  Mean LIN was similar among 
EquiPure™ treatment groups for three of four stallions. 
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 The mean percentages of large heads, proximal droplets, and small proximal 
droplets were similar across treatment groups for three of four stallions (P>0.05).  .  
Mean percentage of large proximal droplets was higher in Group UC than in EquiPure 
treatments for three of four stallions.  The mean percentage of  large distal droplets was 
similar across EquiPure™ treatment groups for each of the four stallions, and was higher 
in EquiPure™ treatment groups than Group UC for three of four stallions (P>0.05). 
Mean bent midpieces was higher in Group CC than all EquiPure™ treatment groups for 
two of four stallions (P<0.05), but no difference was detected among EquiPure™ 
treatment groups for any of the stallions examined.   
 A stallion by treatment interaction was detected for sperm recovery rate.  
Recovery rate (%) was similar (P>0.05) across treatment groups for two stallions, 
whereas recovery rate was higher in 15-mL tubes than 50-mL tubes for one stallion.  For 
the remaining stallion, sperm centrifuged in 15-mL tubes yielded a higher recovery rate 
than Group 50-41mm (16.5mL) (P<0.05; Table 21).  
 
 
 
 
 
 
 
 
 
 
  
 
 
44
Table 13: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion I (mean ± SEM). 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path  
     velocity (μm/s); VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %);  
     COMPαt  =      percentage of sperm with αt  value outside the main population (%).                                                                                             
§   Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
 
 
 
 
 
                                                      EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
MOT 87b (0.9) 89b (2.0) 96a (1.2) 97a (1.0) 97a (0.6) 97a (0) 96a (1.2) 95a (2.5) 
PMOT 63b (2.0) 65b (2.7) 79a (2.3) 77a (2.9) 81a (1.9) 81a (1.5) 79a (0.6) 78a (5.5) 
VCL 179a (8.7) 176a (15.0) 214a (7.3) 217a (6.4) 219a (10.6) 202a (6.2) 203a (6.4) 194a (8.9) 
VAP 110ab (9.0) 96b (10.7) 122a (1.9) 122a (2.3) 125a (1.5) 119ab (1.5) 119ab (1.5) 115ab (3.7) 
VSL 86a (7.8) 70b (7.8) 90a (0.9) 89a (1.2) 93a (1.5) 91a (0.3) 91a (2.3) 89a (2.6) 
STR 75a (0.7) 72a (1.5) 73a (1.2) 72a (1.2) 74a (2.0) 75a (1.0) 75a (1.5) 76a (1.2) 
LIN 49a (2.2) 41a (1.8) 44a (1.8) 43a (1.2) 45a (2.6) 47a (1.7) 47a (2.2) 48a (2.0) 
COMPαt 8a (1.4) 7a (7.1) 2b (0.2) 4b (1.5) 4b (1.0) 3b (0.5) 2b (0.4) 4b (0.4) 
  
 
 
45
Table 14: Effect of treatment on sperm morphology variables for Stallion I (mean ± SEM). 
                                                                  EquiPure™  Treatment 
Laboratory Parameters* 
 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
Morphologically Normal 61b (3.5) 60b (0.3) 80a (0.9) 78a (2.3) 79a (2.9) 78a (0.3) 81a (1.5) 80a (3.2) 
Abnormal Heads 5a (1.5) 4a (0.9) 2a (0.7) 2a (1.2) 3a (1.3) 3a (1.2) 2a (1.3) 2a (1.2) 
Craters 2a (0.3) 0a (0.3) 1a (0.7) 1a (0.6) 1a (0.7) 0a (0.3) 2a (1.2) 1a (0.7) 
Small Heads 2a (0.3) 3a (0.9) 1a (0) 1a (0.7) 2a (0) 2a (0.9) 1a (0.3) 1a (0.6) 
Large Heads 1a (1.0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Misshaped Heads 1a (0.7) 1a (0.3) 0a (0) 0a (0) 1a (0.7) 1a (0.7) 0a (0) 0a (0) 
Abnormal Acrosomes 1a (0.7) 0b (0.3) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 
Detached Heads 5a (0.3) 4a (0.6) 3a (0.3) 4a (1.9) 2a (1.5) 4a (0) 3a (1.7) 3a (1.2) 
Proximal Droplets 13a (1.2) 15a (1.2) 8b (0.7) 8b (1.2) 7b (1.5) 7b (1.2) 6b (0.6) 7b (1.5) 
Small Proximal Droplets 9a (0.6) 11a (1.5) 8a (0.6) 7a (1.3) 7a (1.5) 7a (1.2) 6a (0.9) 7a (1.5) 
Large Proximal Droplets 4a (0.6) 4a (1.0) 0b (0.3) 0b (0.3) 0b (0) 0b (0) 0b (0.3) 0b (0) 
Distal Droplets 2a (0.9) 2a (0.6) 1a (0.7) 2a (0.3) 1a (0.9) 1a (0.3) 0a (0.3) 2a (0.6) 
Small Distal Droplets 1a (0.6) 1a (0.3) 1a (0.7) 2a (0.3) 1a (0.9) 1a (0.3) 0a (0.3) 2a (0.6) 
Large Distal Droplets 1a (0.3) 1a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Abnormal Midpieces 5a (1.9) 8a (0.9) 4a (0.6) 5a (0.7) 6a (1.5) 5a (1.2) 6a (0.7) 6a (0.3) 
Bent Midpieces 3ab (0.3) 3a (1.3) 1b (0.6) 0b (0.3) 0b (0.3) 1b (0.7) 1b (0.3) 1b (0.3) 
Bent Tails 0a (0.3) 0a (0.3) 0a (0.3) 0a (0) 0a (0) 0a (0.3) 0a (0) 0a (0) 
Coiled Tails 3ab (1.5) 4a (0.7) 0b  (0.3) 0b (0) 1b (0.3) 0b (0.3) 0b (0.3) 0b (0.3) 
Premature Germ Cells 0a (0.3) 0a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 1a (0.7) 0a (0) 
§   Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=3).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=3).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=3).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=3).  
g  50-35mm (12,5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=3). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=3). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
  
 
 
46
Table 15: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion II (mean ± SEM). 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path  
     velocity (μm/s); VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %);  
     COMPαt  =      percentage of sperm with αt  value outside the main population (%).                                                                                             
§   Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a,b and c) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
 
 
 
 
 
                                                     EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
MOT 67ab (6.0) 63b (3.2) 85a (4.9) 87a (4.3) 86a (5.2) 87a (3.5) 87a (3.2) 87a (3.6) 
PMOT 36b (6.7) 39b (4.9) 67a (4.6) 71a (5.9) 70a (6.4) 73a (4.8) 72a (4.1) 71a (4.0) 
VCL 213a (5.3) 160b (25.4) 220a (7.0) 218a (6.9) 211a (4.5) 215a (7.5) 205a (6.4) 208a (6.6) 
VAP 109a (3.2) 73b (13.0) 111a (4.6) 111a (5.5) 107a (4.4) 110a (5.2) 104a (4.9) 105a (4.3) 
VSL 84a (3.5) 55b (9.9) 86a (4.1) 87a (4.9) 84a (4.3) 88a (4.9) 84a (5.2) 85a (3.8) 
STR 74c (1.5) 74bc (0.9) 77abc (0.9) 78abc (0.9) 78ab (1.2) 80a (0.9) 79ab (0.3) 80a (1.2) 
LIN 39a (0.9) 34b (1.2) 40a (1.2) 41a (1.5) 41a (1.5) 42a (0.9) 41a (1.2) 42a (1.0) 
COMPαt 16a (2.7) 18a (2.2) 8a (2.5) 9a (3.4) 9a (4.3) 6a (1.9) 7a (2.5) 7a (2.7) 
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Table 16: Effect of treatment on sperm morphology variables for Stallion II (mean ± SEM). 
                                                                  EquiPure™ Treatment 
Laboratory Parameters* 
 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
Morphologically Normal 42b (2.2) 39b (1.2) 67a (2.3) 62a (1.5) 63a (1.7) 62a (1.7) 61a (2.4) 57a (3.3) 
Abnormal Heads 6a (1.5) 6a (0.9) 3a (1.9) 5a (1.7) 4a (1.0) 5a (1.7) 4a (0.9) 6a (2.0) 
Craters 1a (0.6) 2a (1.0) 1a (0.6) 1a (0) 0a (0.3) 2a (0.9) 2a (1.2) 2a (0.3) 
Small Heads 1a (0.7) 2a (0.9) 1a (1.3) 1a (0.9) 2a (0.6) 2a (0.7) 1a (0.6) 2a (1.0) 
Large Heads 1a (0.7) 0a (0) 0a (0.3) 0a (0) 0a (0.3) 0a (0) 0a (0) 0a (0) 
Misshaped Heads 3a (1.2) 2a (1.0) 1a (0.7) 3a (2.2) 1a (0.3) 1a (0.7) 0a (0.3) 2a (1.2) 
Abnormal Acrosomes 2a (0.7) 0a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Detached Heads 15a (5.0) 12a (1.7) 13a (5.5) 10a (5.2) 9a (2.9) 10a (3.9) 6a (1.9) 7a (1.2) 
Proximal Droplets 13a (2.3) 14a (1.9) 8a (1.2) 9a (2.0) 10a (2.5) 11a (1.2) 12a (1.7) 12a (1.5) 
Small Proximal Droplets 10a (3.5) 7a (3.5) 8a (1.2) 9a (2.2) 10a (2.7) 11a (1.2) 11a (1.9) 11a (0.9) 
Large Proximal Droplets 3b (1.2) 8a (2.2) 0b (0) 0b (0.3) 0b (0.3) 0b (0) 1b (0.7) 1b (0.6) 
Distal Droplets 6a (0.6) 8a (4.0) 3a (1.7) 4a (1.2) 3a (0.6) 4a (1.2) 3a (0.7) 6a (1.2) 
Small Distal Droplets 3a (0.3) 7a (3.3) 3a (1.7) 4a (1.2) 3a (0.3) 4a (1.2) 3a (0.7) 5a (1.0) 
Large Distal Droplets 3a (0.3) 1b (0.7) 0b (0) 0b (0) 0b (0.3) 0b (0.3)  0b (0) 1b (0.3) 
Abnormal Midpieces 5a (1.7) 9a (1.8) 4a (1.3) 8a (0.9) 8a (0.6) 6a (1.2) 10a (1.5) 9a (1.7) 
Bent Midpieces 4ab (1.7) 7a (2.0) 1b (0) 1b (0.3) 2b (0.3) 2b (0.6) 2b (1.2) 0b (0) 
Bent Tails 2a (0.3) 1a (0.3) 1a (0.7) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Coiled Tails 4a (0.6) 2b (0.3) 1b (0.3) 1b (0.7) 1b (0.6) 0b (0) 2b (0.6) 1b (0.3) 
Premature Germ Cells 1a (0.9) 0a (0.3) 0a (0) 0a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 
§   Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
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Table 17: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion III(mean ± SEM). 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path  
     velocity (μm/s); VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %);  
     COMPαt  =      percentage of sperm with αt  value outside the main population (%).                                                                                             
§   Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a,b,c,d and e) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
 
 
 
 
 
                                                    EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
MOT 70b (2.3) 78ab (1.9) 90a (3.7) 88ab (4.6) 89a (3.5) 88ab (2.9) 87ab (3.8) 87ab (2.4) 
PMOT 41b (2.6) 49ab (2.0) 73a (6.7) 71a (7.7) 72a (6.4) 71a (6.7) 70a (6.1) 69a (4.7) 
VCL 231a (10.7) 227a (5.6) 255a (13.7) 243a (13.6) 245a (13.1) 229a (11.0) 222a (14.0) 216a (8.5) 
VAP 127a (3.1) 118a (2.5) 137a (8.5) 131a (8.0) 132a (7.6) 125a (7.7) 121a (7.8) 118a (5.0) 
VSL 99a (1.8) 89a (1.2) 108a (7.5) 105a (6.5) 106a (6.1) 102a (7.0) 100a (6.2) 98a (4.4) 
STR 74d (0.9) 71e (0.7) 77c (1.0) 79bc (0.9) 79bc (0.3) 80abc (1.0) 80ab (0.3) 82a (0.6) 
LIN 43a (1.2) 38b (0.3) 43a (1.0) 44a (0.9) 44a (0.9) 45a (1.3) 46a (0.3) 47a (1.0) 
COMPαt 35a (3.6) 33a (5.3) 14b (4.3) 14b (4.5) 14b (4.7) 13b (2.2) 15b (2.9) 13b (1.4) 
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Table 18: Effect of treatment on sperm morphology variables for Stallion III (mean ± SEM). 
                                                               EquiPure™ Treatment 
Laboratory Parameters* 
 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
Morphologically Normal 26b (1.2) 30b (3.2) 59a (3.7) 56a (1.9) 56a (3.1) 57a (6.7) 56a (3.9) 55a (4.0) 
Abnormal Heads 8a (0.9) 7a (1.2) 4a (1.0) 3a (0.9) 5a (0) 4a (1.8) 5a (0.9) 4a (2.0) 
Craters 3a (0.3) 3a (0.9) 1a (0.3) 1a (0.6) 1a (0.6) 1a (1.3) 2a (0.7) 3a (0.9) 
Small Heads 1a (1.3) 1a (0.9) 2a (1.0) 1a (0.7) 1a (0.6) 2a (0.7) 2a (1.2) 1a (0.7) 
Large Heads 1b (0.3) 0b (0.3) 0b (0) 1a (0.7) 0b (0) 0b (0) 0b (0) 0b (0) 
Misshaped Heads 2ab (0.3) 2ab (0.9) 1b (0.3) 0b (0.3) 3a (0.6) 1b (0.7) 0b (0) 1b (0.6) 
Abnormal Acrosomes 1a (0.6) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Detached Heads 24a (6.7) 9ab (1.3) 8ab (5.2) 9ab (4.7) 7ab (1.5) 6ab (2.6) 7ab (0.3) 5b (0.3) 
Proximal Droplets 20a (2.7) 27a (1.2) 18a (2.3) 18a (2.4) 23a (2.6) 22a (2.3) 21a (0.3) 21a (1.0) 
Small Proximal Droplets 13a (3.2) 20a (3.9) 16a (1.5) 18a (2.1) 21a (2.6) 21a (2.8) 20a (0.6) 21a (1.0) 
Large Proximal Droplets 8a (0.9) 7ab (3.2) 2b (1.3) 0b (0.3) 2b (0.7) 1b (0.6) 1b (0.7) 0b (0) 
Distal Droplets 3a (0.6) 3a (0.7) 2a (0.6) 1a (1.3) 2a (1.2) 2a (1.2) 2a (0.7) 2a (0) 
Small Distal Droplets 0a (0.3) 3a (0.7) 2a (0.9) 1a (1.3) 1a (1.3) 2a (1.2) 1a (0.3) 2a (0) 
Large Distal Droplets 3a (0.3) 1b (0.7) 0b (0.3) 0b (0) 0b (0.3) 0b (0) 0b (0.3) 0b (0) 
Abnormal Midpieces 9a (2.7) 15a (3.0) 8a (3.8) 10a (0.3) 6a (2.0) 8a (2.4) 10a (2.0) 11a (2.6) 
Bent Midpieces 4a (0.3) 3a (0.6) 0a (0.3) 2a (1.0) 1a (0.7) 3a (1.7) 1a (0.3) 2a (0.3) 
Bent Tails 1a (0.6) 1a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Coiled Tails 2a (0.6) 3a (2.1) 1a (0.7) 1a (0.7) 1a (0.7) 0a (0.3) 0a (0.3) 1a (0.7) 
Premature Germ Cells 3a (1.8) 3a (1.3) 0a (0) 0a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 
§   Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
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Table 19: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion IV (mean ± SEM). 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path  
     velocity (μm/s); VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %);  
     COMPαt  =      percentage of sperm with αt  value outside the main population (%).                                                                                             
§   Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a,b,c and d) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
 
 
 
 
 
                                                    EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
MOT 59b (3.5) 62b (2.3) 90a (1.2) 92a (1.8) 90a (1.2) 84a (4.0) 85a (2.5) 84a (3.5) 
PMOT 29b (1.2) 30b (2.7) 73a (1.7) 74a (4.1) 73a (2.0) 63a (6.7) 65a (4.7) 63a (6.7) 
VCL 185b (1.2) 188ab (11.8) 221a (3.5) 218ab (4.2) 218ab (4.2) 197ab (7.0) 196ab (8.9) 191ab (10.7) 
VAP 103ab (1.2) 98b (6.3) 120a (1.9) 119a (3.5) 120a (3.0) 109ab (3.2) 109ab (5.3) 107ab (6.6) 
VSL 81bc (1.2) 74c (4.0) 98a (1.2) 97a (3.0) 99a (2.5) 91ab (2.2) 92ab (3.7) 91ab (5.6) 
STR 72c (0.3) 71c (1.3) 79b (0.9) 80ab (0.6) 81ab (0.3) 82ab (1.0) 82ab (0.3) 83a (0.6) 
LIN 42c (0.3) 39d (0.7) 45b (0.9) 46b (0.9) 46ab (0.7) 47ab (0.9) 47ab (0.3) 49a (0.3) 
COMPαt 18a (1.4) 21a (3.4) 4b (0.6) 5b (0.6) 3b (0.4) 4b (1.0) 4b (0.4) 4b (0.7) 
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Table 20: Effect of treatment on sperm morphology variables for Stallion IV (mean ± SEM). 
                                                                   EquiPure™ Treatment 
Laboratory Parameters* 
 
 
 
 
Group UCa† 
 
 
Group CCb† 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
Morphologically Normal 21b (1.8) 24b (4.1) 47a (2.8) 49a (1.5) 45a (2.3) 49a (3.2) 46a (2.6) 45a (2.8) 
Abnormal Heads 7a (1.5) 3a (1.5) 3a (1.2) 2a (0.6) 4a (1.2) 4a (0.7) 4a (0.9) 4a (1.2) 
Craters 2a (0.9) 1a (0.6) 1a (0.7) 0a (0.3) 1a (0.6) 0a (0.3) 1a (0.3) 1a (0.6) 
Small Heads 3a (0.3) 1a (0.3) 1a (0.7) 0a (0.3) 1a (0.6) 2a (0.6) 2a (0.7) 1a (0.6) 
Large Heads 1a (0.3) 0a (0) 0a (0.3) 1a (0.3) 1a (0.7) 0a (0.3) 0a (0.3) 0a (0) 
Misshaped Heads 2a (0.6) 1a (0.6) 1a (0.6) 1a (0.6) 2a (0.3) 1a (1.0) 1a (0.6) 2a (0.6) 
Abnormal Acrosomes 0a (0) 0a (0 ) 0a (0) 0a (0) 0a (0) 0a (0) 1a (0.7) 0a (0) 
Detached Heads 4a (2.1) 6a (2.3) 4a (0.9) 4a (0.6) 4a (1.9) 5a (2.2) 4a (0) 5a (0.9) 
Proximal Droplets 9a (2.5) 10a (1.7) 21a (6.0) 21a (0.6) 18a (3.3) 14a (1.5) 15a (2.3) 18a (3.5) 
Small Proximal Droplets 3b (1.2) 7ab (0.7) 16a (5.8) 15a (1.5) 12ab (3.0) 10ab (2.6) 12ab (1.8) 11ab (2.5) 
Large Proximal Droplets 6a (1.5) 3a (1.0) 5a (1.8) 6a (1.2) 6a (0.3) 4a (1.3) 4a (2.0) 7a (1.0) 
Distal Droplets 1a (0.6) 1a (0.6) 4a (2.5) 4a (2.0) 6a (2.7) 4a (1.2) 5a (2.6) 3a (1.9) 
Small Distal Droplets 0a (0.3) 0a (0.3) 4a (2.5) 3a (2.3) 5a (2.8) 3a (1.5) 4a (2.6) 2a (0.9) 
Large Distal Droplets 1a (0.3) 1a (0.7) 0a (0) 1a (0.3) 0a (0.3) 1a (0.7) 1a (0) 1a (1.0) 
Abnormal Midpieces 12a (0.7) 11a (1.8) 6a (2.1) 9a (2.3) 10a (3.2) 8a (1.5) 11a (3.0) 8a (1.8) 
Bent Midpieces 34a (3.4) 30a (4.4) 9b (1.5) 9b (1.5) 8b (1.7) 13b (3.1) 11b (3.4) 11b (4.1) 
Bent Tails 1a (0.3) 2a (1.2) 2a (0.9) 0a (0) 1a (1.3) 1a (1.0) 1a (1.0) 2a (1.5) 
Coiled Tails 6ab (3.5) 12a (5.4) 5ab (1.2) 2ab (0.3) 4ab (0.9) 3ab (0.3) 2b (1.2) 4ab (0.6) 
Premature Germ Cells 3a (1.7) 2a (0 ) 0a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
§   Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.  Original means       
    and SEM values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within  
    laboratory parameter means with different letters (a and b) differ (P < 0.05). 
a  Group UC = uncenrifuged (raw) semen (n=3). 
b  Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12).  
d  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™ (n=12).    
e  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ (n=12).  
f   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12).  
g  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™ (n=12). 
h  50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ (n=12). 
†  Control Samples. 
‡  Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
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Table 21: Recovery rates for Experiment 2 (mean ± SEM). 
*  Total RR = total sperm recovery rate for all four stallions (%); RR-St I = sperm recovery rate for Stallion I (%);                                            
    RR-St II = sperm recovery rate for Stallion II (%); RR-St III = sperm recovery rate for Stallion III (%); RR-St IV =   
    sperm recovery rate for Stallion IV (%).   
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical          
    analysis.  Original means  and SEM values are presented in table to ease interpretation but statistical tests were    
    conducted on transformed data.  Among treatment and within laboratory parameter means with different letters (a,b    
    and  c) differ (P< 0.05). 
a  15-28mm (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™.  
b  15-35mm (3mL) = 15-mL tube containing 3 mL of bottom-layer EquiPure™.    
c  15-41mm (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™.  
d   50-28mm (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™.  
e  50-35mm (12.5mL) = 50-mL tube containing 12.5 mL of bottom-layer EquiPure™. 
f   50-41mm (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™.  
† Each tube had 1 mL extended semen layered on the EquiPure™ containing 250 – 500 x 106 sperm and 200 x g for    
   30 minutes. 
 
 
 
 
Experiment 3 
 
 The main effects of sperm number (1x, 2x, 3x, or 4x) exposed to density gradient 
centrifugation and centrifugation tube type (15-mL, 50-mL) on sperm quality are 
presented in Tables 22 and 23.  Overall, twenty two of the twenty seven experimental 
endpoints (VCL, VAP, STR, LIN, COMPαt, abnormal heads, craters, small heads, large 
heads, misshaped heads, abnormal acrosomes, detached heads, proximal droplets, small 
proximal droplets, large proximal droplets, distal droplets, small distal droplets, large 
distal droplets, bent midpieces, bent tails, coiled tails, and premature germ cells) were 
not affected by EquiPure™ treatment group (P>0.05).  Treatment 50-1x was yielded 
lower values for MOT than all other EquiPure™ treatment groups (P<0.05).  Mean 
                       EquiPure™ Treatment 
Laboratory 
Parameters* 
 
15-28mm 
 (2mL)c‡ 
15-35mm  
(3mL)d‡ 
15-41mm  
(4mL)e‡ 
50-28mm 
(9mL)f‡ 
50-35mm 
(12.5mL)g‡ 
50-41mm 
(16.5mL)h‡ 
Total RR 43.8a (7.3) 41.2a (6.7) 41.8a (6.0) 35.1b (3.9) 32.8b (3.9) 31.3b (2.7) 
RR-St I 76.3a (2.8) 72.0a (3.9) 70.0a (2.0) 45.0b (6.7) 49.3b (3.3) 39.3b (5.7) 
RR-St II 21.0a  (3.0) 21.0a (2.6) 24.3a (2.7) 21.0a (1.0) 19.3a (1.2) 23.3a (1.2) 
RR-St III 21.0a (3.6) 20.3a (3.7) 23.0a (3.8) 26.7a (2.3) 21.7a (0.3) 24.7a (4.1) 
RR-St IV 56.7a (1.2) 51.3ab (2.0) 49.7ab (3.2) 47.7abc (1.0) 40.7bc (1.2) 37.7c (1.7) 
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PMOT, was slightly higher in Group 15-4x than Group 50-1x (P<0.05).  Mean VSL was 
lower for Groups 15-3x and 15-4x than for Groups 15-1x, 50-1x, and 50-2x (P<0.05).  
Group 50-4x was lower than Groups 15-2x, 15-3x, and 50-2x for percentage of 
morphologically normal sperm (P<0.05).  The percentage of abnormal midpieces was 
higher in Group 50-4x than in Groups 15-2x, 15-3x, 50-1x, and 50-2x (P<0.05).   
 All EquiPure™ treatment groups were superior to both controls for mean values 
for MOT, PMOT, COMPαt, morphologically normal sperm, bent midpieces and coiled 
tails (P<0.05).  Mean VCL, VAP, and VSL were slightly higher in all EquiPure™ 
treated groups than Group CC (P<0.05).  Mean values for STR, large proximal droplets, 
and premature germ cells were lower in all EquiPure™ treated groups than Group UC 
(P<0.05).  The percentage of abnormal heads was significantly higher in the Group UC 
than in Groups 15-1x, 15-2x, 15-3x, 50-1x and 50-2x (P<0.05).  The mean percentage of 
large heads was slightly higher in Group UC than in Groups 15-1x, 15-3x, 50-1x, and 
50-2x (P<0.05).  The mean percentage of detached heads was lower in Groups 15-1x and 
15-3x than Group UC (P<0.05).  The mean percentage of large distal droplets was lower 
in Groups 50-1x and 50-4x than in Group UC (P<0.05).  The mean percentage of 
abnormal midpieces were higher in Group CC than Groups 15-2x, 15-3x, and 50-2x 
(P<0.05).  Mean values for  LIN, small heads, misshaped heads, small proximal droplets, 
distal droplets, small distal droplets, and bent tails were similar among the EquiPure™ 
treatment groups and the control groups (P>0.05).         
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Table 22: Main effects of treatment on sperm motility and chromatin quality (COMPαt) variables for four stallions 
 (mean ± SEM). 
 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
    VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with 
    αt  value outside the main population (%). 
§   Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means and SEM 
    values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter, 
    means with different letters (a,b,c and d) differ (P < 0.05). 
a   Group UC = uncenrifuged (raw) semen (n=12). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=12). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=12). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=12).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=12). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=12).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=12). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=12). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=12). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=12).   
†   Control Samples. 
 
 
 
 
 
                                                                                EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
MOT 84c  (2.4) 86c (2.0) 96a (0.5) 97a (0.4) 97a (0.4) 97a (0.4) 94b (1.0) 95a (0.6) 96a (0.5) 96a (0.4) 
PMOT 57d (4.0) 61c (3.5) 79ab (1.4) 81ab (1.1) 81ab (0.9) 82a (1.0) 78b (2.0) 79ab (1.4) 81ab (1.1) 81ab (1.2) 
VCL 207a (11.1) 182b (6.2) 205a (7.2) 199a (7.5) 195a (7.1) 195a (7.2) 201a (6.9) 202a (6.6) 199a (6.6) 198a (6.8) 
VAP 102a (5.6) 88b (2.9) 102a (3.5) 98a (3.6) 95a (3.2) 95a (3.5) 101a (3.5) 100a (3.5) 98a (3.4) 97a (3.4) 
VSL 71bc (3.1) 61d (1.3) 73ab (2.4) 70bc (2.4) 68c (2.0) 69c (2.2) 76a (2.7) 74ab (2.6) 72bc (2.6) 71bc (2.6) 
STR 69b (1.7) 70a (1.3) 72a (0.9) 73a (0.9) 73a (0.8) 73a (0.8) 75a (1.2) 74a (1.2) 74a (1.1) 74a (1.1) 
LIN 38a (3.1) 35a (0.6) 37a (0.4) 37a (0.4) 36a (0.5) 36a (0.5) 39a (0.7) 38a (0.6) 37a (0.6) 37a (0.6) 
COMPαt 5a (0.6) 5a (0.5) 2b (0.3) 2b (0.4) 2b (0.3) 2b (0.3) 2b (0.4) 2b (0.3) 2b (0.3) 2b (0.4) 
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Table 23:  Main effects of treatment on sperm morphology variables for four stallions (mean ± SEM). 
                                                              EquiPure™ Treatment 
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
Morphologically Normal 46d (3.5) 49d (3.2) 69abc (2.6) 72a (2.8) 71ab (3.0) 69abc (2.4) 68abc (2.3) 71ab (2.9) 66bc (2.9) 64c (2.8) 
Abnormal Heads 8a (1.0) 7ab (0.8) 4c  (0.8) 5c (0.9) 5bc (0.9) 7abc (0.9) 5bc (0.7) 5bc (0.8) 7abc (0.8) 6abc (1.0) 
Craters 2a (0.4) 1ab (0.1) 1ab (0.3) 1ab (0.2) 1ab (0.2) 2ab (0.3) 1ab (0.3) 1b (0.1) 2ab (0.4) 1ab (0.3) 
Small Heads 1a (0.3) 2a (0.2) 1a (0.2) 1a (0.3) 1a (0.3) 1a (0.4) 1a (0.4) 1a (0.3) 2a (0.3) 1a (0.2) 
Large Heads 2a (0.6) 1ab (0.5) 1b (0.2) 1ab (0.3) 1b (0.2) 1ab (0.4) 0b (0.2) 0b (0.2) 1ab (0.3) 1ab (0.4) 
Misshaped Heads 4a (0.7) 3a (0.5) 2a (0.4) 2a (0.4) 3a (0.4) 3a (0.6) 3a (0.4) 3a (0.6) 3a (0.5) 3a (0.6) 
Abnormal Acrosomes 2a (0.4) 2ab (0.5) 1b (0.2) 1b (0.3) 1b (0.2) 0b (0.2) 0b (0.2) 1b (0.2) 1b (0.2) 1ab (0.3) 
Detached Heads 4a (0.8) 3ab (0.6) 1b (0.4) 2ab (0.5) 1b (0.5) 2ab (0.5) 2ab (0.7) 2ab (0.6) 2ab (0.7) 3ab (0.7) 
Proximal Droplets 14ab (2.4) 16a (3.5) 12ab (1.9) 10b (1.7) 10b (1.3) 10b (1.3) 11b (1.6) 10b (2.0) 11b (1.6) 11b (1.6) 
Small Proximal Droplets 7a (1.4) 10a (2.1) 8a (1.5) 7a (1.4) 7a (0.9) 7a (1.0) 9a (1.6) 8a (1.8) 8a (1.3) 7a (1.3) 
Large Proximal Droplets 7a (1.4) 6ab (1.5) 4bc (0.9) 3c (0.7) 3c (0.7) 3c (0.6) 2c (0.4) 2c (0.5) 3c (0.6) 3c (0.5) 
Distal Droplets 3a (0.8) 4a (1.2) 4a (1.5) 3a (1.2) 3a (1.2) 3a (0.8) 3a (1.0) 3a (0.8) 3a (0.7) 2a (0.6) 
Small Distal Droplets 1a (0.4) 3a (1.0) 2a (0.5) 2a (0.7) 2a (0.5) 2a (0.5) 3a (0.8) 2a (0.6) 2a (0.4) 1a (0.4) 
Large Distal Droplets 3a (0.5) 1ab (0.3) 2ab (1.2) 1ab (0.4) 2ab (0.8) 1ab (0.4) 1b (0.2) 1ab (0.4) 1ab (0.3) 1b (0.3) 
Abnormal Midpieces 8abc (1.4) 9ab (1.4) 7abc (1.1) 6c (0.7) 6c (1.2) 8abc (1.1) 7bc (1.2) 6c (1.0) 8abc (1.2) 10a (1.2) 
Bent Midpieces 5a (1.2) 4a (1.0) 1b (0.4) 2b (0.5) 1b (0.5) 1b (0.5) 2b (0.8) 1b (0.2) 2b (0.7) 2b (0.6) 
Bent Tails 1a (0.4) 1a (0.3) 0a (0.1) 0a (0.1) 0a (0.2) 0a (0.1) 0a (0.2) 0a (0.1) 0a (0.1) 0a (0.2) 
Coiled Tails 8a (1.3) 5b (1.1) 1c (0.4) 1c (0.4) 1c (0.4) 1c (0.3) 1c (0.5) 1c (0.4) 1c (0.5) 1c (0.4) 
Premature Germ Cells 2a (0.4) 0b (0.2) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.   Original means and SEM values are presented in table to ease   
    interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter, means with different letters (a,b,c and d) differ (P<0.05). 
a   Group UC = uncenrifuged (raw) semen (n=12). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=12). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=12). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=12).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=12). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=12).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=12). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=12). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=12). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=12).   
†   Control Samples.
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 Significant stallion-by-treatment interactions (P<0.05) were detected for 13 of 27 
variables (MOT, PMOT, VCL, VAP, VSL, STR, large heads, proximal droplets, small 
proximal droplets, small distal droplets, large distal droplets, bent midpieces, coiled tails 
and premature germ cells) and these data are presented in Tables 24 through 31.  Mean 
MOT was similar among EquiPure™ treatment groups for two of four stallions 
(P>0.05).  For one stallion, MOT was higher in Groups 15-1x, 15-2x, 15-3x, and 15-4x 
than in Groups 50-1x and 50-2x (P<0.05).  Mean MOT was lower in Group 50-1x than 
the other EquiPure™ treatment groups for the remaining stallion (P<0.05).  Mean MOT 
was higher in EquiPure™ treatment groups than control groups for each of the four 
stallions (P<0.05). Mean PMOT was similar among EquiPure™ treatment groups for 
three of four stallions (P>0.05). For one stallion, Groups 15-3x and 15-4x yielded higher 
values than Group 50-1x for PMOT (P<0.05).  For each of the stallions, mean PMOT in 
EquiPure™ treatment groups was higher than that for control groups (P<0.05). Values 
for Mean VCL, VAP, and were similar among EquiPure™ treatment groups for each of 
the four stallions, and mean VCL was higher in all EquiPure™ treatment groups than 
Group CC in one of four stallions. Mean VSL was similar among EquiPure™ treatment 
groups for two of the four stallions, was higher in all EquiPure™ treatment groups than 
Group CC in two of four stallions.  
The percentages of large heads, proximal droplets, small distal droplets were 
similar across all treatment groups for three of four stallions (P>0.05).   No difference 
was detected for percentage large distal droplets across treatment groups for any of the 
four stallions (P>0.05).Mean percentage of bent midpieces was similar among 
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EquiPure™ treatment groups for each of the four stallions, and was higher in 
EquiPure™ treatment groups than one of the control groups  for two of four stallions.   
Mean percentage of coiled tails was similar among EquiPure™ treatment groups for 
each of the four stallions (P>0.05), and was higher in EquiPure™ treatment groups than 
Group UC for three of four stallions (P<0.05).  Mean percentage of percentage of 
premature germ cells was similar among EquiPure™ treatment groups for each of the 
four stallions (P>0.05), and was higher in EquiPure™ treatment groups than Group UC 
for each of the four stallions.      
 Over all stallions, sperm recovery rate (%) was lower in Group 15-4x than all 
other treatment groups (P<0.05), and was higher in Group 15-1x than Groups 50-3x and 
50-4x (P<0.05;Table 32).  A stallion-by-treatment interaction was detected for recovery 
rate (P<0.05).  Mean recovery rate was similar across treatment groups for two of four 
stallions (P>0.05).  For one stallion, sperm recovery rate in Group 15-4x was lower than 
all other treatment groups.  In another stallion, Groups 15-3x and 15-4x yielded lower 
sperm recovery rates than did Groups 15-1x, 15-2x and 50-1x.   
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Table 24: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion 1 (mean ± SEM). 
 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
    VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with                                                                             
    αt  value outside the main population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means and SEM                                     
    values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter,  
    means with different letters (a,b and c) differ (P < 0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
      †   Control Samples. 
  
  
 
 
 
 
                                                     EquiPure™ Treatment    
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
MOT 90c (0.9) 90c (0.3) 96a (0.6) 97a (0) 96a (0) 96a (0.3) 94b (0.3) 94b (0.3) 95ab (0.7) 95ab (0.3) 
PMOT 66b (2.0) 67b (3.8) 80a (2.3) 82a (2.7) 81a (1.9) 82a (1.3) 82a (0.7) 79a (1.5) 82a (1.2) 82a (1.7) 
VCL 247a (10.2) 188b (10.4) 206b (5.2) 196b (13.9) 192b (12.5) 192b (15.0) 183b (10.3) 186b (11.0) 190b (10.4) 185b (12.0) 
VAP 120a (5.8) 90ab (5.9) 99ab (3.5) 93ab (7.5) 90ab (7.2) 91ab (8.7) 88ab (6.1) 88ab (6.9) 90ab (6.7) 87b (6.4) 
VSL 81a (2.6) 63a (2.0) 72a (1.7) 68a (3.5) 65a (3.5) 66a (4.9) 69a (4.4) 67a (4.6) 68a (5.0) 65a (4.0) 
STR 68b (1.5) 71ab (2.3) 74ab (1.5)  74ab (2.3) 74ab (2.1) 74ab (1.7) 79a (0.9) 77a (0.9) 76a (0.7) 76a (0.7) 
LIN 46a (12.5) 35a (0.6) 37a (0.7) 36a (0.6) 35a (0.3) 35a (0.3) 39a (0.6) 37a (0.6) 37a (0.9) 36a (0.3) 
COMPαt 3ab (0.2) 4a (0.5) 1b (0.2) 1b (0.3) 1b (0.2) 2b (1.1) 1b ( 0.2) 1b (0.1) 2b (0.1) 1b (0.1) 
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Table 25:  Effect of treatment on sperm morphology variables for Stallion 1 (mean ± SEM). 
                                                EquiPure™ Treatment    
Laboratory 
 Parameters* 
 
 
 
Group 
UCa† 
 
 
Group 
CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
Morphologically 
Normal 47b (4.7) 52ab (0.6) 68a (3.8) 68a (4.0) 67a (5.8) 66a (3.3) 64a (2.2) 66a (4.7) 65a (3.8) 61a (2.6) 
Abnormal Heads 6a (1.3) 6a (0.6) 4a (1.0) 4a (1.5) 5a (0.3) 6a (0.3) 7a (1.2) 5a (0.9) 6a (0.7) 5a (0.3) 
Craters 3a (1.2) 2a (0) 1a (0.3) 0a (0.3) 1a (0) 2a (1.0) 2a (0.6) 1a (0) 2a (0.7) 1a (0) 
Small Heads 1a (0.3) 1a (0.3) 1a (0.7) 2a (0.9) 1a (0.3) 2a (0.3) 1a (1.0) 2a (0.7) 1a (0.7) 1a (0.6) 
Large Heads 1a (0.3) 0a (0.3) 0a (0) 0a (0) 0a (0.3) 0a (0) 0a (0.3) 0a (0) 0a (0.3) 1a (0.7) 
Misshaped Heads 2a (0.9) 2a (0.3) 2a (1.0) 2a (0.3) 3a (0.3) 3a (0.9) 3a (0.3) 2a (0.6) 2a (0.3) 3a (0.3) 
Abnormal Acrosomes 3a (0.9) 2a (1.1) 1a (0.3) 1a (0.7) 1a (0.3) 0a (0.3) 0a (0.3) 0a (0.3) 1a (0.6) 1a (0.6) 
Detached Heads 5a (1.9) 3a (0.3) 0a (0.3) 1a (0.7) 1a (0.9) 2a (1.2) 3a (1.7) 2a (0.3) 1a (1.0) 3a (1.2) 
Proximal Droplets 13a (2.9) 12a (1.8) 10a (1.7) 8a (1.0) 9a (2.1) 9a (1.5) 10a (0.6) 9a (2.9) 8a (2.4) 9a (2.2) 
Small Proximal Droplets 6a (1.4) 8a (2.4) 6a (1.0) 5a (1.0) 7a (0.9) 7a (2.0) 8a (0.3) 7a (2.1) 7a (1.5) 5a (2.4) 
Large Proximal Droplets 7a (2.7) 3a (0.7) 4a (1.0) 3a (1.0) 2a (1.2) 2a (0.9) 2a (0.3) 2a (0.9) 1a (0.9) 3a (0.9) 
Distal Droplets 5a (1.5) 10a (1.8) 11a (4.1) 8a (2.9) 9a (3.2) 5a (1.9) 8a (1.2) 7a (1.2) 5a (1.7) 4a (1.9) 
Small Distal Droplets 1c (0.7) 8a (1.5) 4abc (0.9) 5abc (1.5) 4abc (0.6) 3abc (0.3) 7ab (0.3) 5abc (0.6) 3bc (1.2) 3abc (1.2) 
Large Distal Droplets 4a (1.5) 1a (0.3) 7a (3.9) 3a (1.5) 5a (2.6) 2a (1.5) 1a (0.6) 2a (1.0) 2a (0.7) 2a (0.7) 
Abnormal Midpieces 5a (2.1) 9a (1.5) 5a (2.3) 7a (0.3) 5a (0.6) 8a (0.6) 5a (1.2) 7a (2.0) 11a (1.5) 11a (1.5) 
Bent Midpieces 6a (0.7) 3ab (1.5) 1ab (1.0) 3ab (0.9) 1ab (1.0) 1ab (1.0) 1b (0) 0b (0.3) 2ab (0.9) 4ab (0.9) 
Bent Tails 2a (0.6) 1a (0.7) 0a (0) 0a (0.3) 1a (0.7) 0a (0.3) 0a (0.3) 1a (0.3) 0a (0.3) 1a (0.7) 
Coiled Tails 8a (0.7) 3b (0) 0c (0.3) 0c (0.3) 1c (0.6) 1c (0.6) 1c (0.7) 2c (0.6) 1c (0.3) 1c (0.7) 
Premature Germ Cells 1a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
  §  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.   Original means and SEM values are presented in table 
    to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter, means with different letters (a,b and c)  
    differ (P<0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
†   Control Samples. 
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Table 26: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion 2 (mean ± SEM). 
 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
    VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with                                                                             
    αt  value outside the main population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means and SEM                                     
    values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter,  
    means with different letters (a,b and c) differ (P < 0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
      †   Control Samples. 
  
 
 
 
                                                    EquiPure™ Treatment       
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
MOT 90b (0.9) 91b (1.2) 97a (0.6) 97a (0.3) 98a (0.6) 97a (0.7) 96a (0.3) 97a (0.6) 97a (0.3) 98a (0) 
PMOT 71b (2.0) 71b (1.2) 84a (0.9) 85a (1.8) 85a (0.7) 86a (0.6) 84a (1.2) 85a (3.0) 85a (1.5) 86a (1.2) 
VCL 175a (5.5) 152b (2.6) 174a (3.3) 170ab (5.2) 167ab (4.3) 167ab (4.1) 183a (1.8) 182a (5.5) 177a (7.5) 176a (6.7) 
VAP 90ab (3.5) 75b (0.9) 87ab (2.7) 85ab (3.8) 83ab (3.1) 82ab (2.6) 95a (1.2) 93a (3.8) 89ab (5.2) 89ab (4.2) 
VSL 68ab (2.3) 55c (0.6) 64ab (0.7) 62bc (2.0) 61bc (1.5) 61bc (1.2) 72a (2.1) 69ab (2.5) 65ab (2.2) 65ab (2.6) 
STR 76a (0.6) 75a (0.3) 75a (1.7) 74a (1.2) 75a (1.2) 75a (0.7) 77a (1.3) 75a (1.7) 74a (2.5) 75a (1.2) 
LIN 40ab (0) 37c (0.6) 39abc (0.3) 38bc (0.3) 38bc (0) 38bc (0) 41a (1.2) 39abc (0.9) 38bc (0.6) 39abc (0.3) 
COMPαt 4a (0.6) 5a (0.7) 2b (0.5) 2b (0.1) 1b (0.2) 2b (0.2) 2b (0.2) 1b (0.1) 2b (0.1) 2b (0.1) 
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Table 27:  Effect of treatment on sperm morphology variables for Stallion 2(mean ± SEM). 
                                                 EquiPure™ Treatment    
Laboratory 
 Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
Morphologically Normal 34c (2.9) 45b (2.0) 58a (2.6) 64a (5.5) 61a (1.7) 62a (0.6) 61a (3.6) 62a (0.3) 57a (1.5) 57a (1.7) 
Abnormal Heads 12a (1.8) 11ab (0.3) 6b (0.3) 8ab (0.7) 9ab (0.7) 9ab (0.7) 7ab (1.5) 8ab (0.9) 10ab (0.6) 10ab (2.4) 
Craters 2a (0.3) 1a (0.3) 0a (0) 1a (0.3) 1a (0.3) 2a (0.3) 1a (0.6) 1a (0.3) 2a (0.6) 1a (0.9) 
Small Heads 1a (0.7) 1a (0.3) 1a (0) 2a (0.3) 2a (0.9) 0a (0.3) 2a (0.6) 1a (0) 2a (0.6) 1a (0.3) 
Large Heads 4a (1.3) 4ab (0.7) 1b (0.3) 2ab (0.9) 2ab (0.3) 3ab (0.6) 1ab (0.7) 1ab (0.7) 2ab (0.3) 3ab (0.7) 
Misshaped Heads 4a (1.2) 4a (0.3) 3a (0.3) 3a (0.6) 4a (0) 4a (0.9) 3a (0.3) 5a (0.9) 4a (0.3) 6a (0.9) 
Abnormal Acrosomes 2a (0.6) 3a (1.2) 1a (0.6) 1a (0.3) 0a (0) 0a (0) 1a (0.7) 1a (0.7) 1a (0.3) 1a (1.0) 
Detached Heads 2a (0.6) 2a (1.3) 1a (0.7) 1a (0.6) 1a (0.7) 1a (0.3) 1a (0.7) 1a (0.6) 2a (0.3) 1a (1.0) 
Proximal Droplets 20a (2.6) 20a (2.3) 21a (1.5) 17a (0.9) 14a (1.8) 14a (0.3) 17a (2.9) 20a (0.3) 17a (0.6) 15a (2.3) 
Small Proximal Droplets 11a (3.3) 12a (1.7) 14a (1.3) 12a (2.3) 11a (1.5) 10a (0.6) 15a (2.6) 17a (1.2) 12a (1.2) 11a (1.0) 
Large Proximal Droplets 9a (1.5) 8ab (0.7) 6ab (2.7) 4ab (1.8) 3ab (0.6) 4ab (0.7) 2b (0.3) 3ab (1.2) 5ab (0.6) 4ab (1.5) 
Distal Droplets 5a (1.7) 3a (1.2) 2a (0.3) 3a (2.0) 3a (0.6) 3a (1.8) 1a (0.3) 2a (0.9) 3a (1.5) 2a (0.9) 
Small Distal Droplets 2a (0.9) 1a (0.9) 1a (0.6) 3a (1.5) 2a (0.7) 2a (1.2) 1a (0.6) 2a (0.3) 2a (0.7) 2a (0.7) 
Large Distal Droplets 3a (1.2) 2a (0.3) 1a (0.3) 1a (0.7) 1a (0.3) 1a (0.6) 0a (0.3) 1a (0.7) 1a (0.9) 1a (0.3) 
Abnormal Midpieces 12a (2.1) 12a (2.0) 10a (0.6) 6a (1.2) 12a (0.9) 11a (1.7) 12a (2.0) 7a (1.9) 10a (1.5) 13a (0.3) 
Bent Midpieces 4a (1.2) 1b (0.7) 1b (0.7) 0b (0.3) 1b (1.0) 0b (0.3) 0b (0.3) 0b (0) 0b (0.3) 0b (0.3) 
Bent Tails 0a (0.3) 1a (0.9) 0a (0) 0a (0.3) 0a (0) 0a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 
Coiled Tails 6a (1.9) 2b (0.7) 1b (0.3) 0b (0) 0b (0.3) 0b (0) 1b (0.3) 0b (0.3) 0b (0.3) 0b (0.3) 
Premature Germ Cells 2a (1.0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.   Original means and SEM values are presented in table to ease    
     interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter, means with different letters (a,b and c) differ (P<0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).                                
†   Control Samples. 
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Table 28: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion 3 (mean ± SEM). 
 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
    VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with                                                                             
    αt  value outside the main population (%).                                                                                             
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means and SEM                                     
    values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter,  
    means with different letters (a and b) differ (P < 0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
      †   Control Samples. 
  
 
 
 
 
 
                                                     EquiPure™ Treatment    
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
MOT 85b (2.0) 86b (2.6) 98a (0.3) 97a (0.3) 97a (0)  97a (1.2) 96a (0.3) 98a (0.3) 97a (0.6) 97a (0.3) 
PMOT 55b (0.7) 60b (1.3) 78a (1.9) 79a (1.5) 80a (0.9) 79a (2.0) 77a (2.6) 78a (1.3) 79a (2.7) 78a (2.4) 
VCL 185a (29.0) 185a (3.5) 201a (2.0) 201a (5.2) 197a (8.1) 198a (6.1) 202a (6.0) 206a (1.2) 200a (3.2) 203a (4.3) 
VAP 92a (17.7) 91a (2.1) 103a (2.1) 101a (2.4) 98a (3.2) 100a (2.6) 104a (2.0) 105a (0.7) 101a (2.9) 103a (2.7) 
VSL 62a (9.7) 61a (2.0) 71a (2.8) 70a (2.6) 68a (2.4) 69a (2.4) 73a (1.5) 72a (2.6) 70a (2.6) 72a (3.3) 
STR 69a (3.8) 68a (1.9) 69a (1.2) 70a (1.3) 70a (1.5) 70a (1.8) 71a (2.3) 69a (1.8) 71a (2.3) 70a (2.1) 
LIN 35a (0.7) 34a (1.2) 36a (1.2) 36a (1.2) 37a (1.2) 37a (1.5) 38a (1.9) 37a (1.5) 37a (1.5) 37a (1.5) 
COMPαt 5a (0.7) 4a (0.3) 1b (0.1) 1b (0.2) 3b (0.4) 2b (0.2) 2b (0.2) 2b (0.2) 1b (0.2) 2b (0.2) 
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Table 29:  Effect of treatment on sperm morphology variables for Stallion 3 (mean ± SEM). 
                                             EquiPure™ Treatment    
Laboratory 
 Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
Morphologically Normal 60a (7.3) 52a (13.3) 79a (4.5) 83a (4.0) 83a (4.2) 80a (4.7) 78a (3.5) 84a (5.4) 79a (5.2) 77a (6.2) 
Abnormal Heads 6a (2.3) 4a (1.9) 1a (1.3) 1a (1.3) 2a (1.7) 2a (1.9) 2a (0.9) 2a (1.5) 3a (1.2) 3a (1.2) 
Craters 1a (0.7) 1a (0.3) 0a (0) 0a (0.3) 1a (0.7) 0a (0.3) 0a (0.3) 0a (0.3) 1a (0.3) 0a (0.3) 
Small Heads 1a (1.0) 2a (0.7) 1a (0.7) 0a (0.3) 0a (0) 1a (1.3) 1a (1.0) 1a (0.7) 1a (0.7) 1a (0.6) 
Large Heads 2a (1.2) 0a (0.3) 0a (0) 0a (0.3) 0a (0) 0a (0) 0a (0.3) 0a (0) 0a (0.3) 0a (0) 
Misshaped Heads 2a (1.2) 1a (1.0) 1a (0.7) 0a (0.3) 1a (1.0) 1a (0.7) 1a (0.3) 1a (1.0) 0a (0.3) 1a (0.9) 
Abnormal Acrosomes 0a (0) 0a (0) 0a (0) 0a (0) 0a (0.3) 0a (0) 0a (0) 0a (0.3) 0a (0) 0a (0) 
Detached Heads 1a (0.9) 3a (1.5) 0a (0) 0a (0) 0a (0.3) 0a (0.3) 1a (0.6) 1a (1.0) 0a (0) 1a (0.7) 
Proximal Droplets 20ab (2.3) 28a (10.3) 15ab (0.3) 12ab (1.2) 12ab (2.4) 12ab (1.8) 14ab (1.9) 9b (2.1) 13ab (3.1) 15ab (2.5) 
Small Proximal Droplets 10a (0.9) 16a (5.9) 10a (1.7) 9a (0.7) 8a (0.3) 9a (0.3) 11a (1.2) 6a (1.2) 10a (2.6) 11a (1.3) 
Large Proximal Droplets 11a (2.8) 12a (4.6) 5a (2.0) 3a (1.8) 4a (2.6) 4a (1.9) 3a (1.7) 3a (1.5) 3a (1.5) 4a (1.2) 
Distal Droplets 2a (0.9) 3a (1.5) 1a (0.7) 1a (0.6) 0a (0.3) 2a (1.2) 2a (1.2) 1a (0.9) 2a (1.2) 1a (0.6) 
Small Distal Droplets 1a (0.6) 1a (0.9) 1a (0.7) 0a (0.3) 0a (0.3) 1a (1.3) 1a (0.9) 1a (0.9) 1a (0.6) 1a (0.3) 
Large Distal Droplets 2a (0.7) 1a (0.7) 0a (0) 1a (0.3) 0a (0) 0a (0.3) 0a (0.3) 0a (0) 1a (0.7) 0a (0.3) 
Abnormal Midpieces 3a (0.9) 3a (3.0) 4a (2.3) 2a (1.2) 1a (0.6) 2a (0.9) 2a (0) 2a (1.2) 2a (1.9) 3a (1.5) 
Bent Midpieces 1b (0.6) 4a (0.3) 0b (0) 0b (0.3) 1b (0.3) 1b (0.7) 1b (0.6) 1b (0.3) 0b (0.3) 0b (0.3) 
Bent Tails 1a (0.6) 1a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
Coiled Tails 3a (2.4) 2a (1.9) 0a (0) 0a (0) 0a (0) 1a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 
Premature Germ Cells 2a (0.3) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 0a (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.   Original means and SEM values are presented in table to ease  
    interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter, means with different letters (a and b) differ (P<0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
†   Control Samples.
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Table 30: Effect of treatment on sperm motility and chromatin quality (COMPαt) variables for Stallion 4 (mean ± SEM). 
 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity (μm/s); VAP = average-path velocity (μm/s); 
    VSL = straight-line velocity (μm/s); STR = straightness ([VAP/VCL]100; %); LIN  = linearity ([VSL/VCL]100; %); COMPαt  =  percentage of sperm with                                                                             
    αt  value outside the main population (%).                                                                                              
§  Percentage data (MOT, PMOT, STR, LIN, COMPαt) were arc sine-root transformed for normalization prior to statistical analysis.  Original means and SEM                                     
    values are presented in table to ease interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter,  
    means with different letters (a,b,c and d) differ (P < 0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
             †   Control Samples. 
  
 
 
 
 
 
 
                                                             EquiPure™ Treatment    
Laboratory 
Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
MOT 71c (1.7) 76c (2.0) 94a (1.2) 95a (1.0) 95a (0.9) 96a (0.9) 89b (1.5) 93a (0.6) 94a (0.9) 95a (0.3) 
PMOT 37c (3.1) 43c (4.0) 75ab (3.5) 78ab (0.3) 79a (0.9) 82a (1.5) 69b (2.3) 76ab (2.0) 79ab (1.3) 79ab (2.0) 
VCL 220a (8.2) 202b (5.8) 240a (4.4) 231a (6.4) 225a (4.0) 225a (4.3) 234a (4.8) 232a (4.7) 230a (2.2) 229a (2.4) 
VAP 107ab (6.0) 97b (3.2) 118a (2.6) 112a (2.7) 107ab (1.8) 106ab (2.6) 117a (0.6) 114a (1.0) 112a (0.6) 110a (1.2) 
VSL 71cd (3.5) 65d (0.3) 86ab (0.3) 81ab (1.5) 77bc (1.2) 77bc (1.8) 90a (2.6) 86ab (2.5) 84ab (3.2) 82ab (3.8) 
STR 63b (2.3) 66ab (2.0) 72ab (2.2) 72ab (1.7) 71ab (0.9) 72ab (1.5) 75a (2.1) 74a (2.8) 74a (2.3) 74a (2.7) 
LIN 32a (1.2) 32a (0.9) 36a (0.9) 36a (1.0) 35a (0.7) 35a (1.0) 39a (1.7) 38a (1.7) 37a (1.9) 37a (2.2) 
COMPαt 8a (0.6) 8a (0.1) 4b (0.1) 4b (0.8) 4b (0.2) 3b (0.5) 4b (0.7) 4b (0.4) 4b (0.6) 4b (0.4) 
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Table 31:  Effect of treatment on sperm morphology variables for Stallion 4 (mean ± SEM). 
                                                  EquiPure™ Treatment    
Laboratory 
 Parameters* 
 
 
 
Group UCa† 
 
 
Group CCb† 15-1xc 15-2xd 15-3xe 15-4xf 50-1xg 50-2xh 50-3xi 50-4xj 
Morphologically Normal 42c (2.7) 47c (4.0) 69ab (1.5) 73a (1.7) 72a (0.3) 67ab (1.2) 66ab (1.5) 71ab (1.5) 63b (2.3) 62b (1.3) 
Abnormal Heads 9a (1.7) 8a (0.6) 7a (1.5) 7a (0.3) 6a (1.0) 8a (0.6) 5a (0.6) 7a (0.3) 7a (1.0) 7a (0.9) 
Craters 1a (0.6) 1a (0) 2a (0.3) 1a (0.3) 2a (0.7) 2a (0.6) 1a (0.6) 1a (0.3) 1a (1.3) 2a (0.3) 
Small Heads 1a (0.7) 2a (0.6) 1a (0.6) 1a (0.7) 1a (0.6) 1a (0.6) 1a (0) 2a (0.6) 1a (0.3) 1a (0.6) 
Large Heads 1a (0.6) 0a (0.3) 0a (0.3) 1a (0.9) 0a (0.3) 1a (0.7) 0a (0) 0a (0) 0a (0) 1a (0.7) 
Misshaped Heads 5a (1.5) 5a (0.3) 3a (0.6) 3a (0.3) 3a (0) 4a (0.7) 3a (0.6) 5a (0.9) 4a (0.3) 4a (0.6) 
Abnormal Acrosomes 3a (0.7) 1a (0.3) 1a (0) 1a (0.6) 1a (0.3) 1a (0.7) 0a (0.3) 1a (0.3) 0a (0.3) 1a (0.9) 
Detached Heads 7a (0.3) 5a (1.7) 2a (1.5) 4a (0.3) 3a  (0.7) 4a (0.9) 5a (1.8) 5a (0.9) 6a (0.7) 6a (0.3) 
Proximal Droplets 3a (0.9) 5a (0.6) 4a (0.7) 2a (0) 5a (0.7) 4a (1.2) 4a (0.6) 2a (0.7) 5a (1.5) 4a (0.9) 
Small Proximal Droplets 1a (0.6) 2a (0.9) 2a (0.6) 1a (0) 3a (0.6) 2a (0.9) 2a (0.6) 1a (0.6) 2a (0.3) 2a (0.6) 
Large Proximal Droplets 2a (0.7) 3a (0.3) 2a (1.2) 1a (0) 2a (0.9) 2a (0.3) 2a (0) 1a (0.3) 3a (1.3) 2a (0.3) 
Distal Droplets 1a (0.7) 2a (1.7) 2a (1.2) 0a (0.3) 1a (0.9) 1a (0.7) 2a (1.5) 3a (1.7) 1a (0.9) 1a (1.0) 
Small Distal Droplets 0a (0.3) 1a (1.0) 1a (0.9) 0a (0.3) 1a (0.7) 0a (0.3) 2a (1.2) 2a (1.2) 1a (0.3) 1a (0.7) 
Large Distal Droplets 1a (0.6) 1a (0.7) 0a (0.3) 0a (0) 1a (0.3) 0a (0.3) 1a (0.3) 1a (0.6) 1a (0.7) 0a (0.3) 
Abnormal Midpieces 11a (2.1) 12a (1.0) 10a (2.0) 7a (1.2) 6a (0.6) 11a (0.7) 7a (0.9) 8a (1.0) 9a (1.5) 12a (0.9) 
Bent Midpieces 10a (2.3) 9ab (2.1) 3c (0.7) 3c (0.9) 3c (1.2) 3bc (1.2) 6abc (0.9) 2c (0.3) 5abc (1.2) 4bc (0.9) 
Bent Tails 2a (1.2) 0a (0.3) 0a (0.3) 0a (0.3) 0a (0) 0a (0) 1a (0.6) 0a (0) 0a (0.3) 0a (0) 
Coiled Tails 13a (1.5) 10a (0.9) 2b (1.2) 3b (0.6) 2b (1.2) 2b (0.3) 3b (1.5) 2b (1.2) 3b (1.5) 3b (0.3) 
Premature Germ Cells 4a (0.3) 1b (0.7) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 0b (0) 
§  Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical analysis.   Original means and SEM values are presented in table to ease      
   interpretation but statistical tests were conducted on transformed data.  Among treatment and within laboratory parameter, means with different letters (a,b and c) differ (P<0.05). 
a   Group UC = uncenrifuged (raw) semen (n=3). 
b   Group CC = centrifuged semen in 50-mL conical tubes with 3.5 mL Cushion Fluid and 1000 x g for 20 minutes (n=3). 
c  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
d  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3).   
e  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
f   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).  
g   50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes (n=3). 
h   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes (n=3). 
i    50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes (n=3). 
j   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes (n=3).   
†   Control Samples.
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Table 32: Recovery rates for Experiment 3 (mean ± SEM). 
*  Total RR = total sperm recovery rate for all four stallions (%); RR-St 1 = sperm recovery rate for Stallion 1 (%); RR-St 2 =                     
    sperm recovery rate for Stallion 2 (%); RR-St 3 = sperm recovery rate for Stallion 3 (%); RR-St 4 = sperm recovery rate     
    for Stallion 4 (%).   
§   Percentage data (All Laboratory Parameters) were arc sine-root transformed for normalization prior to statistical          
    analysis.  Original means  and SEM values are presented in table to ease interpretation but statistical tests were conducted on    
    transformed data.  Among treatment and within laboratory parameter means with different letters (a,b,c and d) differ (P< 0.05). 
a  15-1x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
b  15-2x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30 minutes. 
c  15-3x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30 minutes. 
d   15-4x = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30 minutes. 
e  50-1x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 1 mL of extended semen containing 250 – 500 x 106 sperm and 200 x g for 30 minutes. 
f   50-2x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 2 mL of extended semen containing 500 – 1000 x 106 sperm and 200 x g for 30  
   minutes. 
g   50-3x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 3 mL of extended semen containing 750 - 1500 x 106 sperm and 200 x g for 30  
   minutes. 
h   50-4x = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended semen containing 1000 - 2000 x 106 sperm and 200 x g for 30    
    minutes. 
 
 
 
 
                       EquiPure™ Treatment 
Laboratory 
Parameter* 
 15-1xa 15-2xb 15-3xc 15-4xd 50-1xe 50-2xf 50-3xg 50-4xh 
Total RR 71.0a (3.8) 68.8ab (3.2) 61.7ab (3.4) 50.4c (3.2) 67.0ab (3.6) 64.9ab (2.8) 62.1b (2.9) 60.6b (3.5) 
RR-St 1 71.0a (10.7) 68.0a (12.1) 69.3a (6.9) 56.7a (8.7) 57.7a (11.3) 58.7a (9.5) 61.7a (4.7) 60.3a (5.5) 
RR-St 2 81.7a  (2.0) 76.0ab (4.2) 56.3c (5.5) 42.3d (6.4) 75.7ab (2.4) 70.3abc (1.3) 65.3abc (2.2) 63.7bc (5.8) 
RR-St 3 65.0a (3.8) 69.0a (3.6) 68.3a (6.6) 56.0a (5.1) 64.7a (0.9) 65.3a (1.8) 64.3a (5.2) 56.0a (12.1) 
RR-St 4 66.3a (3.8) 62.3a (1.9) 52.7a (4.5) 46.7b (3.3) 70.0a (8.3) 65.3a (6.8) 57.0a (10.7) 62.3a (6.1) 
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DISCUSSION AND SUMMARY 
 Several studies have been conducted with density gradient centrifugation in 
human artificial reproductive techniques [33-38].  However, there is only limited data 
available regarding the effects of density gradient centrifugation on the quality of equine 
spermatozoa [5-6,42-43].  For the equine species, three previous studies show that 
density gradient centrifugation yields an improvement in motion and sperm morphologic 
characteristics [6,42-43].  The present study was designed to evaluate sperm motion and 
sperm morphologic characteristics, as well as DNA integrity (SCSA) before, and 
following, density gradient centrifugation.  Unlike previous studies that only included 
fertile stallions, this study encompassed both fertile and subfertile stallions.  Various 
treatments were applied to the density gradient centrifugation process in an effort to 
determine ways to maximize sperm yields and semen quality, while identifying ways to 
simplify the technique for use in the clinical setting.  
 Based on the previous studies with human semen and preliminary work in our 
laboratory, in this study we anticipated that a number of experimental endpoints would 
be improved following density gradient centrifugation [33-38].  In Experiment 1, we 
hypothesized that single-layer density gradient centrifugation would yield similar values 
to the two-layer technique for sperm motility, morphology, and chromatin integrity.  We 
selected 4 mL of EquiPure™ Bottom Layer in the one-layer treatment to compare to the 
two layer media (2 mL EquiPure™ Top Layer over 2 mL EquiPure™ Bottom Layer) so 
that the depth of the media would be comparable.  In general, the one-layer treatment 
yielded superior values for sperm motion characteristics and sperm chromatin 
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characteristics, and yielded similar results to the conventional two-layer treatment for 
sperm morphologic characteristics, when compared to the conventional two-layer 
treatment.  This finding is in contrast to the findings of Morrell et al. (2008), where the 
recovery rate was similar for both treatment groups [43].  The volume of density 
gradient and time of centrifugation were identical in the current study to that of Morrell 
et al., but the centrifugation force differed [43]. One consideration, as noted by Morrell 
et al., is that the interface between the density gradient layers plays an important role in 
selecting the sperm that pass through to the pellet [43].  However, our view is that by 
using the single layer method the sperm would have to pass through the same distance of 
the denser gradient as opposed to half the distance through the lighter gradient and half 
the distance through the heavy gradient.  In the current study, the single layer 
centrifugation yielded superior sperm motion characteristics and chromatin integrity, but 
similar in sperm morphologic characteristics as the two-layer method.  Our data support 
the use of a one-layer technique making it a more user-friendly procedure in a clinical 
setting.  Instead of layering two times, by using only a single layer it is necessary to 
layer only once allowing the procedure to be simplified.  Based on these results, we used 
the single layer density gradient method for Experiments 2 and 3. 
 The stallions used in Experiment 1 were thought to be fertile.  All four stallions 
showed an improvement in total motility, progressive motility, morphologically normal 
sperm, and DNA quality.  The one-layer density gradient centrifugation eliminated bent 
midpieces for Stallion A.  For Stallion B, EquiPure™ decreased the percentage of bent 
midpieces and the one-layer method eliminated coiled tails.  For Stallions A and B the 
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sperm recovery rates were similar between the two methods.  Stallion C exhibited a 
percentage decrease in abnormal midpieces, bent midpieces, and coiled tails following 
EquiPure™ centrifugation.  For Stallion D, there was a remarkable decrease in the 
percentage of bent midpieces from 26 to 5 in the one-layer method as well as a decrease 
in coiled tails in both methods.  Stallions C and D yielded a higher recovery rate in the 
one-layer method when compared to the two-layer approach.    
 For Experiment 2, we chose to compare the 4 mL volume of EquiPure™ Bottom 
Layer to both a 2 mL and 3 mL volume of EquiPure™ Bottom Layer to determine if 
sperm quality is affected when the volume of the density gradient is altered.  Reducing 
the volume of EquiPure™ Bottom Layer would allow the procedure to be more cost 
effective in a clinical setting.  We found that sperm motility, morphologic characteristics 
and chromatin integrity were similar among the volumes of EquiPure™ Bottom Layer 
density gradient (2, 3, or 4 mL) when used with 15-mL centrifuge tubes.  The volumes 
selected for use with 50-mL conical bottom tubes (9, 12.5, and 16.5 mL) were designed 
to correspond to density gradient heights for the three volumes used in the 15 mL-tubes.  
The 50-mL conical tubes were chosen to evaluate the potential of processing entire 
ejaculates with fewer centrifugation tubes.  Measures of sperm motility, morphologic 
characteristics and chromatin integrity were similar among these density gradient 
volumes applied to the 50-mL tubes.  Furthermore, experimental endpoints were similar 
for measures of semen quality when comparing the 50-mL and 15-mL conical tubes.  
However, sperm recovery rates were generally lower for semen centrifuged in 50-mL 
conical tubes, as compared to 15-mL conical tubes.  These data suggest that 15-mL tubes 
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should be used to maximize sperm recovery when using the single EquiPure™ Bottom 
Layer centrifugation method.  Based on the higher recovery rate and that there was no 
significant statistical difference between the volumes for semen quality the 15-28mm 
(2mL) would be the most cost efficient.  The differences in recovery rate between the 
tube sizes could be due to the ability to see the pellet more clearly in the 15-mL tube. 
 The stallions used in Experiment 2 are different from the stallions used in 
Experiment 1.  Stallion I is a known fertile stallion; Stallions II, III and IV are known 
subfertile stallions.   All four stallions showed an improvement in total motility, 
progressive motility, morphologically normal sperm, and DNA quality.  EquiPure™ 
processing eliminated coiled tails for Stallion I.  The recovery rate differences between 
the 15-mL and 50-mL conical tubes for Stallion I was due to clarity of the pellet as 
described previously.  Stallion II showed a decrease in bent midpieces.  For Stallion III, 
density gradient centrifugation was able to decrease considerably the DNA quality 
percentage which means an improvement.  EquiPure™ processing decreased bent 
midpieces from 34 to 8-13 depending on the treatment for Stallion IV.  Since this 
experiment used known subfertile stallions, it is remarkable to see how that density 
gradient centrifugation can impact a stallion’s semen quality.  
 For Experiment 3, we evaluated the effects of sperm number on sperm recovery 
rate and quality of sperm in recovered pellets.  For this study, we selected the 41mm 
density gradient volume height, to allow further the distance for sperm to traverse 
though the gradient when increasing numbers of sperm above 1 x 109 was applied to the 
gradient.   In this study, no major difference was detected in the resulting semen quality 
  
 
71
as a result of sperm load added to the gradient for either the 15 mL or 50-mL tubes.  
Recovery rate following a 4x sperm load in the 15-mL tubes tended to be lower than that 
of lower sperm loads, whereas a sperm load of 1-4x (representing 500 x 106 to 2 x 109 
sperm) did not affect sperm recovery rate in 50-mL tubes.   The lowered sperm yield for 
a high sperm load in the 15-mL tubes is likely due to the reduced surface area for sperm 
migration into and through the density gradient, as compared to that in the 50-mL tubes. 
Based on the experimental endpoints’ results, the 15-3x would be the most logical 
choice of tube combination to use. It allows you to layer between 750 x 106 and 1 x 109 
sperm per centrifugation tube while keeping the usage of the density gradient medium 
low.  Of clinical importance, density gradient centrifugation of semen with any of the 
techniques applied appeared to result in improved semen quality of recovered sperm, 
when compared to the uncentrifuged and cushion centrifuged control groups.  The 
experimental results also suggest that the two layer protocol can be simplified to a single 
layer method.   
 The stallions used in Experiment 3 were thought to be fertile.  All four stallions 
showed an improvement in total motility, progressive motility, morphologically normal 
sperm, and DNA quality.  EquiPure™ processing eliminated coiled tails for Stallions 1, 
2 and 3.  Also, for Stallion 2 bent midpieces were eliminated.  For Stallion 4, density 
gradient centrifugation decreased coiled tails and bent midpieces.  
 Of clinical importance, density gradient centrifugation of semen with any of the 
techniques applied appeared to result in improved semen quality of recovered sperm, 
when compared to the uncentrifuged and cushion centrifuged control groups.  The 
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experimental results also suggest that the two-layer protocol can be simplified to a one-
layer method.  A summary comparison of best 15-mL and 50-mL treatments for 
Experiments 2 and 3 are presented in Table 33.  For Experiment 2, by processing in 15-
28mm a practitioner can use less EquiPure™ Bottom Layer and recover a higher total 
sperm number when the entire ejaculate is processed.  Since Experiment 2 contained 
three subfertile stallions, the total sperm numbers were significantly lower than the 
stallions used in either of the other experiments.  However, these would be the stallions 
that would utilize the EquiPure™ processing and why it is so important to show the 
impact the process has on subfertile stallions.  For Experiment 3, the 15-3x was similar 
to all parameters when compared to 50-4x.  From the practitioner’s standpoint, even 
though there is a lower total number applied and one might have to use an extra tube 
when processing, one still would be minimizing cost by using the 15-3x treatment.  This 
is because the volume to reach the 41mm height in the 50-mL conical tubes is 16.5mL of 
EquiPure™ Bottom Layer.      
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Table 33: Summary Comparison of Treatments for Experiments 2 and 3(mean ± SEM). 
Experiment 2 Treatments Experiment 3 Treatments 
Laboratory Parameters* 
15-28 (2mL)a 50-28 (9mL)b       15-3x (4mL)c 50-4x (16.5mL)d 
MOT  90a (1.8)   89a (1.9)          97a (0.4) 96a (0.4) 
PMOT 73a (2.3)  72a (2.4)          81a (0.9) 81a (1.2) 
VCL  228a (6.0)  207b (4.9)         195a (7.1) 198a (6.8) 
STR  77b (0.8)  79a (0.8)          73a (0.8) 74a (1.1) 
Morph. Normal  63a (3.8)  62a (3.6)          71a (3.0) 64a (2.8) 
Recovery Rate  44a (7.3)  35b (3.9)          62a (3.4) 61a (3.5) 
TSN (x 109) 1.78a (0.5) 1.33b (0.3)         4.96a (0.4) 4.93a (0.5) 
TSN– TMOT (x 109) 1.60a (0.5) 1.18b (0.3)          4.81a (0.4) 4.73a (0.5) 
TSN– PMOT(x 109)   1.31a (0.4) 0.96b (0.2)          4.05a (0.4) 3.97a (0.4) 
TSN– Morph Norm (x 109) 1.23a (0.4) 0.88b (0.3)         3.60a (0.5) 3.24a (0.4) 
*  MOT = total spermatozoal motility (%); PMOT = progressive sperm motility (%); VCL = curvilinear velocity    
     (μm/s); STR = straightness ([VAP/VCL]100; %);  Morph. Normal = morphologically normal sperm (%); Recovery                                    
     Rate = sperm recovery rate (%); TSN (x 109) = total number of sperm recovered following centrifugation;                             
     TSN-MOT (x 109) = total number of motile sperm recovered following centrifugation;                             
     TSN-PMOT(x 109) = total number of progressively motile sperm recovered following    
     centrifugation; TSN-Norm (x 109) = total number of morphologically normal sperm recovered  
     following centrifugation. Within treatment and within laboratory parameter, means with different   
     letters (a and b) differ (P < 0.05).    
a  15-28 (2mL) = 15-mL tube containing 2 mL of bottom-layer EquiPure™ (n=12). 
b   50-28 (9mL) = 50-mL tube containing 9 mL of bottom-layer EquiPure™ (n=12). 
c   15-3x (4mL) = 15-mL tube containing 4 mL of bottom-layer EquiPure™ and 3 mL of extended semen   
    containing 750 - 1500 x 106 sperm (n=12). 
d   50-4x (16.5mL) = 50-mL tube containing 16.5 mL of bottom-layer EquiPure™ and 4 mL of extended    
     semen containing 1000 - 2000 x 106 sperm (n=12).  
 
 In summary, density gradient centrifugation of stallion semen appears to be a 
useful means of selecting sperm for superior quality.  EquiPure™ improved the 
percentages of total motility, progressive motility, morphologically normal sperm and 
DNA quality for all stallions in the study.  Based on the stallions used in the study, 
EquiPure™ processing would be suitable for a stallion that has an ejaculate with poor 
DNA quality, low motility, and/or morphological defects like bent midpieces, bent tails 
and coiled tails.  The single layer can be reduced to 2 mL in the 15-mL conical tubes to 
be more cost efficient.  No advantage was gained by centrifuging in 50-mL conical 
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tubes.  Based on the volume used of EquiPure™ Bottom Layer used in the 50-mL 
conical tubes in this study it would be less cost efficient to process with these amounts 
when similar results can be obtained with the usage of less medium.  In addition, as total 
sperm number layered over the density gradient increased in 15-mL tubes, the recovery 
rate decreased.  The fertility rate following EquiPure™ Bottom Layer centrifugation in a 
commercial program for several subfertile stallions (unpublished data) has demonstrated 
that single-layer density gradient semen centrifugation in 15-mL tubes is successful and 
that the technique can be applied in the clinical setting.   
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FUTURE AIMS 
 While EquiPure™ appears to be satisfactory as a density gradient medium for 
centrifuged semen, the long term effects remain largely unstudied.  To address this, 
future studies could be directed to evaluating density gradient processed semen after 
cooled storage.  The relationship between laboratory measures of semen quality and 
fertility should also be addressed.   
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